,Rank,NCTId,OutcomeMeasurementLowerLimit,OutcomeMeasurementSpread,PrimaryOutcomeTimeFrame,OutcomeMeasurementValue,OverallOfficialAffiliation,OverallOfficialName,OverallOfficialRole,OverallStatus,OversightHasDMC,PatientRegistry,Phase,PointOfContactEMail,PointOfContactOrganization,PointOfContactPhone,PointOfContactPhoneExt,PointOfContactTitle,PrimaryCompletionDate,PrimaryCompletionDateType,PrimaryOutcomeDescription
0,1,['NCT04371159'],[],[],['11 months'],[],[],[],[],['Completed'],[],[],['Not Applicable'],[],[],[],[],[],"['May 30, 2020']",['Actual'],[]
0,2,['NCT04474496'],[],[],['Baseline'],[],[],[],[],['Enrolling by invitation'],['No'],['No'],[],[],[],[],[],[],"['November 1, 2020']",['Anticipated'],"['Respondents will be asked how COVID-19 has impacted mulitple facets of their lives, including housing, food security, and employment and income']"
0,3,['NCT02801266'],[],[],"['immediately after counseling session', 'immediately after counseling session', 'immediately after counseling session', '6 months from initial clinic visit', 'one year from initial clinic visit']",[],['New York University'],"['James J Jaccard, PhD']",['Principal Investigator'],['Completed'],['No'],[],['Not Applicable'],[],[],[],[],[],['October 2014'],['Actual'],[]
0,4,['NCT01599390'],[],[],"['From July 1997 to April 2009 (i.e., up to almost 12 years)', 'From July 1997 to April 2009 (i.e., up to almost 12 years)']",[],['GlaxoSmithKline'],['GSK Clinical Trials'],['Study Director'],['Completed'],['No'],[],[],[],[],[],[],[],['February 2013'],['Actual'],[]
0,5,['NCT00312702'],"['21.4', '18.5', '82.3', '51.4', 'NA', '10590.0', 'NA', '3397.0']",[],['30 days post vaccination'],"['3', '10', '0', '2', '3', '0', '0', '0', '0', '3', '1', '0', '0', '0', '0', '0', '1', '0', '1', '1', '0', '0', '1', '0', '0', '0', '0', '24.8', '47.1', '1629.9', '834.8', 'NA', '29851.5', 'NA', '10378.5']",['Walter Reed Army Institute of Research (WRAIR)'],"['James F Cummings, MD']",['Principal Investigator'],['Completed'],['Yes'],[],"['Phase 1', 'Phase 2']",['james.cummings@us.army.mil'],['Walter Reed Army Institute of Research'],['301-319-9312'],[],"['James F. Cummings, MD']",['October 2006'],['Actual'],"['An AE was defined as any reaction, side effect, or untoward event that occurred during the course of the trial whether or not the event was considered related to study drug or clinically significant.\n\nGrade 1: Mild Grade 2: Moderate Grade 3: Severe']"
0,6,['NCT00312663'],"['23.7', '-10', 'NA', '51.9', '41.1', 'NA', 'NA', '1774.9', '-10', 'NA', '834.0', '14.0']",[],['30 days post vaccination'],"['5', '9', '0', '4', '0', '0', '1', '1', '1', '1', '1', '2', '1', '2', '0', '0', '0', '2', '36.2', '43.15', 'NA', '514.4', '462.0', 'NA', 'NA', '36527.0', '21.1', 'NA', '9180.0', '30']",['Walter Reed Army Institute of Research (WRAIR)'],"['James F. Cummings, MD']",['Principal Investigator'],['Completed'],['Yes'],[],"['Phase 1', 'Phase 2']",['james.cummings@us.army.mil'],['WRAIR'],['301-319-9312'],[],"['James Cummings, MD']",['October 2006'],['Actual'],"['An AE was defined as any reaction, side effect, or untoward event that occurred during the course of the trial whether or not the event was considered related to the study drug or clinically significant. Grade 1: Mild Grade 2: Moderate Grade 3: Severe']"
0,7,['NCT01153880'],[],[],['First prescription in database for each calendar year between January 2007 and December 2011'],[],['GlaxoSmithKline'],['GSK Clinical Trials'],['Study Director'],['Completed'],['No'],[],[],[],[],[],[],[],['August 2012'],['Actual'],[]
0,8,['NCT02019732'],[],[],['Up to 10 years approximately (Marketscan Commercial Database) and up to 6 years approximately (Marketscan Medicare Supplemental Database).'],[],['GlaxoSmithKline'],['GSK Clinical Trials'],['Study Director'],['Completed'],[],[],[],[],[],[],[],[],['June 2013'],['Actual'],"['- All the events contained within ""potentially influenza-attributable"" office visits. - Weekly proportion of circulating influenza A and B strains determined for each season.']"
0,9,['NCT03972358'],[],[],['Up to 28 days after mifepristone administration'],[],['Gynuity Health Projects'],"['Wendy R Sheldon, PhD']",['Principal Investigator'],['Recruiting'],['No'],[],['Phase 2'],[],[],[],[],[],"['December 31, 2020']",['Anticipated'],['Acceptability of MMR']
0,10,['NCT00948233'],[],[],"['Baseline, immediately following completion of the program, and at 6- and 12-month follow-ups']",[],['M.D. Anderson Cancer Center'],"['Alex Prokhorov, MD, PHD']",['Study Chair'],['Withdrawn'],['No'],[],[],[],[],[],[],[],['July 2016'],['Actual'],[]
0,11,['NCT00026728'],[],[],[],[],[],[],[],['Completed'],[],[],[],[],[],[],[],[],[],[],[]
0,12,['NCT01211990'],[],[],[],[],['National Institute of Mental Health (NIMH)'],"['Maryland Pao, M.D.']",['Principal Investigator'],['Completed'],[],[],[],[],[],[],[],[],[],[],[]
0,13,['NCT02663219'],[],[],"['UP to 24 months', 'Up to 24 months']",[],"['Johns Hopkins University', 'Columbia University']","['Chris Beyrer, MD/MPH', 'Robert H Remien, PhD']","['Study Chair', 'Study Chair']",['Unknown status'],['No'],[],['Not Applicable'],[],[],[],[],[],['February 2019'],['Anticipated'],[]
0,14,['NCT00121108'],[],[],['Through Day 150'],[],['MedImmune LLC'],"['Hason Jafri, M.D.']",['Study Director'],['Completed'],['Yes'],[],['Phase 3'],[],[],[],[],[],['December 2010'],['Actual'],[]
0,15,['NCT01861210'],[],[],['3 months'],[],['Emory University Rollins School of Public Health'],"['Patrick S Sullivan, PhD']",['Principal Investigator'],['Completed'],['No'],[],['Not Applicable'],[],[],[],[],[],['May 2012'],['Actual'],"['Having been punched, hit, or kicked by the partner he tested with, injured to the point of feeling physical pain the day after a fight, or inflicting any of these acts on his partner in the preceding three months.']"
0,16,['NCT02911155'],[],[],['2016-2022'],[],['National Cancer Institute (NCI)'],['Cari M Kitahara'],['Principal Investigator'],['Completed'],[],[],[],[],[],[],[],[],"['May 1, 2020']",['Actual'],['Cancer and other disease risks associated with occupational nuclear medicine radiation exposures']
0,17,['NCT00724867'],"['34', '29', '29', '29', '5', '5', '5', '5', '5', '5', '5', '5', '5', '5', '5', '5', '5', '45', '5', '-75.6', '-84.2', '-84.7', '-90.6', '-90.6', '-90.6', '-90.6', '-96', '-96.5', '-97.5', '-97.5', '-97.5', '-97.5', '-97.5', '-97.5', '-97.5', '-77.6', '-97.5', '40', '43', '38', '46', '36', '55', '51', '47', '58', '64', '56', '54', '47', '50', '51', '76', '79', '56', '3', '3', '4', '3', '4', '4', '3', '3', '4', '4', '3', '5', '5', '6', '6', '10', '7', '22', '4', '-33', '-45.3', '-23.3', '-37.9', '-17.3', '-34.6', '-32.9', '-27.5', '-24.7', '-17.9', '-18', '-32.9', '-34.2', '-36.3', '7.7', '5', '-25.6', '-53.3', '-40', '-57.1', '-33.3', '-20', '-40', '-70', '-42.9', '-30', '-40', '-10', '-40', '-40', '-14.3', '0', '-30', '100', '-53.8', '2', '2', '2', '5', '5', '5', '5', '3', '5', '1', '5', '4', '4', '4', '5', '5', '5', '7', '3', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '6', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '4', '0', '0', '1', '2', '0', '1', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '1', '0', '1', '1', '0', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '1', '0', '1', '1', '1', '2', '1', '1', '1', '2', '1', '0', '2', '0', '1', '1', '2', '2', '2', '4', '1', '11', '7', '1', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '1', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '2', '0', '4', '4', '4', '4', '4', '4', '4', '4', '4', '4', '4', '4', '4', '4', '4', '4', '4', '7', '4', '-91.9', '-94.7', '-95.4', '-96.3', '-96.2', '-97.3', '-96.8', '-97.6', '-97.6', '-98.1', '-98.1', '-96.7', '-97.6', '-97.3', '-96.9', '-95.5', '-84.4', '-98.2', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-78', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-79.4', '-100', '-97.4', '-99', '-100', '-99.2', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-97.1', '-100', '-88.9', '-84.6', '-100', '-97.1', '-92.6', '-92.3', '-97.7', '-96', '-96.2', '-92.9', '-96.2', '-92.3', '-96', '-88.8', '-76.9', '-100', '-95.1', '-96.7', '-97.6', '-98.6', '-98.5', '-98.5', '-98.8', '-98.8', '-100', '-99.2', '-100', '-97.7', '-98.4', '-98', '-97.9', '-96.5', '-87.5', '-99', '-98.5', '-99.7', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-100', '-90.1', '-100', '-91.7', '-94.6', '-95.5', '-96', '-96.3', '-97.3', '-97.8', '-97.8', '-97.8', '-98.1', '-98.1', '-98.5', '-97.6', '-97.8', '-96.9', '-95.6', '-85.4', '-98.2']","['4.46', '4.56', '4.81', '4.83', '5.37', '5.88', '5.39', '4.92', '5.34', '6.51', '8.19', '7.03', '5.46', '6.37', '7.71', '4.77', '9.55', '5.02', '5.51', '13.44', '6.72', '8.58', '1.463', '3.502', '3.239', '3.943', '4.493', '5.059', '2.693', '2.983', '3.77', '3.047', '14.36', '3.56', '5.488', '3.333', '3.473', '3.23', '5.149', '2.401', '4.759', '2.758', '3.972', '2.202', '0.0157', '0.0173', '0.0175', '0.0172', '0.016', '0.0159', '0.0157', '0.0156', '0.0179', '0.0157', '0.0159', '0.0168', '0.0226', '0.0149', '0.0178', '0.0189', '0.0188', '0.0155', '0.0147', '0.0141', '0.0183', '0.0186', '0.0893', '0.1089', '0.1281', '0.1279', '0.1216', '0.1228', '0.1234', '0.1303', '0.1276', '0.125', '0.1407', '0.1281', '0.1547', '0.1169', '0.1227', '0.1269', '0.1401', '0.1425', '0.1121', '0.0141', '0.1295', '0.1401', '1.642', '1.856', '1.884', '2.092', '1.863', '2.087', '2.19', '1.959', '1.876', '2.205', '2.207', '2.112', '2.389', '2.161', '2.164', '2.149', '2.388', '2.297', '2.549', '1.273', '2.969', '2.613', '0.4223', '0.558', '0.5023', '0.5002', '0.5129', '0.5033', '0.5299', '0.5621', '0.572', '0.5809', '0.5678', '0.5924', '0.629', '0.5876', '0.5564', '0.6439', '0.6619', '0.6291', '0.8495', '1.4354', '0.6129', '0.6256', '0.1673', '0.1694', '0.1678', '0.1806', '0.1754', '0.1809', '0.1805', '0.1809', '0.1903', '0.1875', '0.1782', '0.1878', '0.1983', '0.1826', '0.1808', '0.1996', '0.2032', '0.1909', '0.2074', '0.3818', '0.1846', '0.1958', '1.6734', '1.7293', '1.8685', '2.1086', '1.7955', '2.0209', '2.1226', '1.8521', '1.763', '2.1214', '2.1425', '1.9654', '2.2312', '2.0787', '2.1415', '2.1382', '2.3755', '2.2303', '2.4214', '0.5798', '2.9836', '2.5793', '1.6685', '1.7212', '1.8683', '2.1097', '1.8014', '2.0163', '2.1204', '1.8509', '1.7607', '2.1249', '2.1464', '1.9703', '2.2273', '2.0826', '2.1432', '2.1378', '2.3698', '2.2303', '2.4214', '0.5798', '2.8796', '2.5788', '35.71', '42.04', '41.13', '46.11', '46.36', '56.18', '56.8', '56.86', '57.11', '64.11', '60.26', '65.99', '65.69', '62.88', '67.73', '77.75', '64.56', '65.89', '62.84', '83.44', '59.82', '70.29', '0.243', '0.284', '0.291', '0.309', '0.337', '0.341', '0.338', '0.361', '0.362', '0.37', '0.376', '0.395', '0.412', '0.405', '0.393', '0.438', '0.441', '0.404', '0.403', '0', '0.398', '0.415', '2.247', '2.62', '2.683', '2.836', '3.087', '3.321', '3.433', '3.604', '3.545', '3.448', '3.414', '3.596', '3.943', '3.94', '3.561', '4.166', '4.108', '3.807', '3.554', '0.99', '3.613', '3.478', '7.03', '8.17', '8.81', '9.51', '10.2', '11.07', '11.76', '11.93', '11.86', '11.91', '11.82', '12.44', '13.71', '13.6', '13.13', '14.73', '14.98', '12.78', '12.98', '2.83', '12.46', '11.93', '2.17', '2.53', '2.47', '2.69', '2.88', '3.18', '3.25', '3.41', '3.65', '3.6', '3.5', '3.76', '3.69', '4.05', '4.09', '4.14', '4.19', '4.4', '3.92', '0', '3.59', '3.77', '3.73', '4.41', '4.31', '4.59', '4.91', '4.9', '5.08', '5', '5.36', '5.3', '5.22', '5.44', '5.16', '5.55', '5.81', '5.56', '5.87', '5.78', '5.18', '2.12', '5.53', '6.19', '1.4283', '1.4782', '1.9011', '1.5648', '1.5557', '1.6796', '1.7024', '1.7117', '1.6693', '1.6775', '1.721', '1.6526', '1.7712', '1.6054', '1.6972', '1.6668', '1.6683', '1.5362', '1.5417', '1.06', '1.7369', '2.2109', '1.1734', '1.1712', '1.2279', '1.2519', '1.5029', '1.3072', '1.5426', '1.4319', '1.4829', '1.6169', '2.1698', '1.4792', '1.7205', '1.7746', '1.7503', '2.257', '1.8839', '1.9609', '2.2408', '0.4094', '1.3871', '1.4114', '0.0888', '0.0872', '0.0889', '0.0884', '0.0896', '0.0946', '0.0922', '0.09', '0.1004', '0.095', '0.0889', '0.0986', '0.0912', '0.0977', '0.0925', '0.0873', '0.0964', '0.0788', '0.0935', '0.0354', '0.0923', '0.1029', '2.72', '2.62', '2.51', '2.67', '2.64', '2.58', '2.78', '2.75', '2.82', '2.7', '2.79', '2.68', '2.73', '2.62', '3.23', '2.84', '3.14', '3.17', '2.87', '1.41', '2.74', '2.55', '2.8', '2.53', '2.31', '2.43', '2.53', '2.6', '3.03', '3.01', '3.06', '3.28', '2.83', '3.06', '3.02', '3.11', '2.89', '3.1', '3.28', '3.21', '2.49', '2.12', '2.96', '2.65', '0.0673', '0.0625', '0.0599', '0.066', '0.0677', '0.0709', '0.0699', '0.0719', '0.0681', '0.0682', '0.0692', '0.062', '0.0622', '0.067', '0.0664', '0.0691', '0.0681', '0.0644', '0.0599', '0.0283', '0.0676', '0.0728', '0.1857', '0.1851', '0.2027', '0.1825', '0.1926', '0.2219', '0.1968', '0.2129', '0.221', '0.2145', '0.1765', '0.1899', '0.1892', '0.2153', '0.2097', '0.1962', '0.1875', '0.2186', '0.2093', '0.1893', '0.2151', '0.2131', '0.407', '0.412', '0.409', '0.427', '0.413', '0.42', '0.426', '0.418', '0.466', '0.409', '0.417', '0.406', '0.427', '0.431', '0.438', '0.379', '0.387', '0.354', '0.401', '0.212', '0.431', '0.493', '2.67', '2.67', '2.02', '2.46', '2.06', '2.19', '2.58', '2.18', '2.44', '2.54', '2.36', '2.19', '2.37', '2.33', '2.72', '2.97', '2.49', '2.32', '1.95', '1.41', '2.32', '2.33', '4.69', '4.86', '5.31', '5.07', '5.29', '5.76', '4.78', '5.63', '5.61', '5.86', '6.05', '5.52', '6.49', '5.79', '6.38', '5.75', '5.42', '5.09', '5.28', '0.71', '5.57', '5.99', '46.0197', '52.2256', '55.2277', '57.2999', '58.0533', '57.0915', '60.3008', '63.7367', '66.183', '60.2771', '60.7226', '65.2308', '65.6118', '73.3489', '74.9078', '72.282', '60.8139', '66.4246', '62.7192', '16.402', '71.4811', '84.8414', '2.0889', '2.4872', '2.2546', '2.4316', '2.3675', '2.7306', '3.0385', '2.8298', '2.548', '2.6718', '2.823', '2.8668', '2.7449', '2.7954', '2.6834', '2.7018', '2.85', '2.8249', '2.4435', '1.4142', '2.8268', '3.2759', '0.2312', '0.2455', '0.2831', '0.3083', '0.306', '0.3145', '0.3498', '0.38', '0.3784', '0.3981', '0.3628', '0.3724', '0.3652', '0.3971', '0.3985', '0.4482', '0.4424', '0.4682', '0.2808', '0.165', '0.3986', '0.3467', '4.69', '4.86', '5.31', '5.07', '5.29', '5.76', '4.78', '5.63', '5.61', '5.86', '6.05', '5.52', '6.49', '5.79', '6.38', '5.75', '5.42', '5.09', '5.28', '0.71', '5.57', '5.99', '14.89', '11.01', '12.27', '14.12', '14.64', '12.33', '16.67', '12.32', '14.93', '17.02', '24.4', '15.79', '17.15', '20.87', '13.25', '13.96', '15.06', '12.06', '11.39', '4.24', '13.77', '14.46', '13.82', '17.41', '16.72', '16.2', '19.97', '21.17', '21.25', '20.61', '21.89', '29.67', '33.31', '24.75', '26.55', '33.87', '26.36', '25', '24.83', '29.63', '38.97', '24.75', '23.59', '26.98', '11.18', '9.37', '8.14', '11.29', '10.67', '10.97', '12.24', '9.49', '14.63', '14.74', '32.99', '16.27', '15.15', '22.03', '13.55', '13.14', '14.1', '9.66', '8.02', '4.24', '15.07', '12.45', '22.54', '21.44', '20.21', '18.64', '39.98', '27.97', '28.88', '20.1', '31.27', '45.58', '47.03', '32.51', '40.11', '40.3', '37.08', '38.88', '36.19', '35.44', '31.02', '3.54', '35.29', '35.9', '26.46', '29.56', '37.57', '34.88', '35.5', '36.29', '40.42', '40.13', '47.95', '45.12', '53.17', '48.34', '49.81', '72.28', '55.64', '53.17', '57.15', '58.81', '81.78', '0.71', '56.73', '52.66', '9.92', '9.96', '9.92', '11.01', '10.17', '10.32', '10.12', '9.56', '10.52', '9.89', '10.15', '10.25', '10.78', '9.5', '9.94', '9.79', '8.27', '12.73', '9.77', '15.75', '16.14', '14.66', '16.49', '15.22', '16.23', '14.44', '14.61', '15.03', '14.92', '15.29', '15.29', '15.86', '14.73', '14.19', '14.65', '11.73', '6.36', '15.53', '10.113', '10.428', '10.399', '11.099', '11.22', '11.274', '11.269', '11.066', '8.603', '8.3', '8.51', '8.752', '9.314', '9.406', '9.887', '10.107', '23.36', '24.389', '23.409', '24.181', '24.549', '23.636', '24.969', '22.93', '14.693', '15.156', '15.929', '16.069', '17.742', '18.187', '18.693', '19.994', '17.71', '17.46', '17.817', '20.172', '20.662', '19.968', '19.811', '18.551', '21.498', '21.185', '21.994', '22.112', '24.486', '24.81', '26.422', '27.065', '25.714', '27.92', '28.258', '28.237', '28.774', '31.614', '30.385', '33.91', '26.393', '27.106', '26.525', '28.998', '29.839', '30.995', '31.347', '34.385', '26.901', '27.218', '27.989', '28.598', '30.079', '28.695', '31.784', '32.135', '21.449', '22.287', '20.742', '21.742', '24.937', '23.023', '22.709', '22.033', '10.785', '11.414', '11.614', '11.269', '11.962', '11.787', '11.644', '10.949']","['Up to Week 440', 'Up Week 440', 'Up to Week 440', 'Up to Week 440', 'Up to Week 440', 'Up to Week 440', 'Up to Week 440', 'Up to Week 440', 'Up to Week 440', 'Up to Week 440', 'Up to Week 440', 'Up to Week 440', 'Up to Week 440', 'Up to Week 432', 'Up to Week 440', 'Up to Week 432', 'Up to Week 440', 'Up to Week 440']","['267', '260', '235', '206', '184', '167', '145', '87', '31', '112', '33', '30', '25', '22', '24', '16', '13', '3', '134.4', '75.5', '53.6', '32.3', '30', '29.7', '28.5', '27.9', '12.4', '10.1', '9.1', '9.1', '8.2', '6.7', '6.4', '6', '5.3', '5', '4.4', '3.8', '2.3', '1.8', '0.8', '0.5', '0.1', '4', '2.2', '2', '1.7', '1.4', '1.4', '1', '1', '0.7', '0.6', '0.6', '0.5', '0.5', '0.4', '0.3', '0.3', '0.1', '0.1', '0.1', '0.1', '0.1', '0.1', '0.1', '1.3', '1', '0.7', '1.4', '1.7', '2.7', '3.9', '4.5', '4', '4.2', '4.7', '4.7', '3.6', '4.3', '4.8', '4.4', '5', '4.7', '4.7', '8.5', '3.1', '3.3', '-0.05', '-0.66', '-0.04', '-0.42', '0.2', '0.52', '0.24', '0.26', '0.34', '0.39', '1.96', '0.6', '0.5', '0.39', '0.55', '0.72', '0.68', '0.5', '1.85', '1.45', '0.57', '0.33', '0.001', '0.002', '0.003', '0.003', '0.001', '0.002', '0.001', '0.004', '0.004', '0.004', '0.002', '0.003', '0.005', '0.003', '0.003', '0.005', '0.009', '0.002', '0.002', '0.02', '0.005', '0.004', '-0.001', '0.005', '0.008', '0.004', '0.007', '0.006', '-0.009', '-0.002', '-0.023', '-0.034', '-0.032', '-0.038', '-0.019', '-0.027', '-0.038', '-0.017', '-0.026', '-0.031', '-0.032', '-0.08', '-0.026', '-0.022', '0.08', '0.18', '-0.02', '0.04', '-0.01', '-0.19', '-0.27', '-0.33', '-0.42', '-0.29', '-0.35', '-0.4', '-0.18', '-0.4', '-0.24', '-0.22', '0.05', '0.17', '-0.63', '-3.7', '0.09', '-0.11', '0.076', '0.039', '0.002', '0.059', '-0.02', '-0.073', '-0.036', '0.002', '-0.028', '-0.036', '-0.067', '-0.07', '-0.047', '-0.021', '-0.008', '0.011', '0.143', '0.126', '0.059', '0.765', '-0.025', '0.029', '0.028', '0.036', '0.024', '0.054', '0.044', '0.053', '0.052', '0.059', '0.071', '0.065', '0.084', '0.095', '0.086', '0.072', '0.049', '0.098', '0.097', '0.101', '0.024', '0.03', '0.075', '0.093', '-0.027', '0.1', '-0.059', '-0.086', '-0.037', '-0.176', '-0.283', '-0.397', '-0.443', '-0.288', '-0.342', '-0.392', '-0.207', '-0.424', '-0.251', '-0.315', '-0.176', '-0.025', '-0.681', '-4.44', '0.058', '-0.214', '-0.028', '0.098', '-0.059', '-0.086', '-0.044', '-0.177', '-0.284', '-0.397', '-0.444', '-0.286', '-0.342', '-0.39', '-0.207', '-0.422', '-0.249', '-0.313', '-0.179', '-0.025', '-0.681', '-4.44', '0.046', '-0.215', '2.9', '-1.1', '-2', '-5.9', '-8.4', '-17.5', '-18.8', '-17', '-22.4', '-14.6', '-17', '-19', '-17.6', '-18.9', '-23.7', '-14', '-24.7', '-30.5', '-40.7', '37', '-9.4', '-8', '0', '0.01', '0.04', '0.03', '0.06', '0.06', '0.04', '0.06', '0.04', '0.03', '0.07', '0.08', '0.1', '0.13', '0.19', '0.2', '0.19', '0.25', '0.39', '0.1', '0.26', '0.2', '0.16', '0.11', '0.31', '0.2', '0.73', '0.81', '1.09', '1.4', '1.53', '1.39', '1.67', '1.78', '1.98', '2.16', '2.49', '2.34', '1.86', '2.68', '3.49', '0.7', '3.25', '3.04', '0', '0.3', '0.5', '0.5', '2.1', '2.5', '2.4', '3.7', '3.9', '2.5', '3.2', '3.7', '3.7', '3.7', '4.2', '3.3', '2.6', '5.2', '8.4', '-3', '7.2', '6.5', '-0.3', '0.1', '0.3', '0.4', '1.1', '1.1', '1.2', '1.3', '1.4', '1.3', '1.5', '1.7', '2', '1.8', '1.8', '1.4', '1.6', '2', '2.9', '1', '2.2', '1.8', '-1.3', '-1.9', '-2.1', '-2.6', '-1.8', '-2.2', '-2.6', '-2.6', '-3', '-3.4', '-3.6', '-3.4', '-3.4', '-4', '-3.5', '-4.3', '-4.3', '-4.1', '-3', '-1.5', '-2.6', '-3.1', '0.026', '-0.1695', '-0.1612', '-0.1732', '-0.1013', '-0.1873', '-0.0134', '-0.0552', '-0.0472', '-0.09', '-0.1162', '-0.0331', '0.0176', '-0.0029', '-0.0858', '0.0246', '-0.008', '-0.1152', '-0.1603', '-0.1805', '0.0501', '0.3248', '0.1088', '0.2006', '0.0881', '0.2158', '0.1482', '0.1146', '0.323', '0.1927', '0.1719', '0.2737', '0.2523', '0.2579', '0.2964', '0.2903', '0.3897', '0.297', '0.5098', '0.449', '0.7571', '0.8845', '0.2986', '0.3354', '0.0071', '-0.0043', '-0.0023', '-0.0156', '0.0007', '-0.0017', '-0.0019', '-0.0009', '-0.0109', '-0.0115', '-0.0072', '-0.0181', '-0.0011', '-0.0107', '0.0007', '0.0014', '0.0063', '-0.0123', '0.0021', '-0.005', '0.0151', '0.0046', '-0.2', '-0.4', '-0.2', '-0.1', '-0.2', '0', '-0.5', '-0.5', '-0.9', '-0.6', '-0.6', '-0.9', '-0.7', '-0.8', '-0.7', '-0.7', '-0.3', '-0.5', '-0.7', '-1', '0.1', '0', '0.2', '0.1', '0.3', '0.5', '0', '0.1', '0.1', '-0.1', '0.1', '-0.4', '-0.3', '-0.3', '-0.1', '0', '0.3', '0.4', '0.5', '0.5', '1.1', '1.5', '-0.5', '0.1', '0.002', '-0.005', '0.004', '0.001', '0.001', '0.003', '0.003', '0.007', '0.011', '0.009', '0.012', '0.017', '0.014', '0.017', '0.003', '0.004', '0.001', '-0.006', '0.016', '0.02', '0.03', '0.028', '0.0165', '-0.0065', '0.0106', '-0.0039', '0.0019', '-0.0133', '0.0099', '0.0033', '0.0017', '-0.0022', '-0.0102', '-0.015', '-0.0035', '-0.004', '-0.0139', '0.0296', '0.031', '-0.0223', '-0.0054', '0.1467', '0.0161', '0.0438', '0.07', '0.02', '0.02', '0.03', '-0.04', '0.01', '0.02', '0.01', '0.01', '-0.02', '0.04', '0', '0.06', '-0.03', '0.06', '0.04', '0.06', '0', '0.1', '0.05', '0.11', '0.07', '0.4', '0', '0.3', '0.3', '-0.1', '0', '0', '-0.1', '0.4', '0.2', '0.1', '0.1', '0', '0.1', '0.3', '0.3', '0.3', '0.2', '0.4', '-1', '0.1', '0.8', '-0.2', '-0.5', '-0.6', '-0.4', '-0.2', '-0.2', '0.3', '0.8', '0.9', '1.2', '0.9', '1', '1.2', '1.2', '1', '1.1', '0.7', '0.8', '0.4', '-0.5', '1.1', '1.3', '-1.653', '-5.5803', '-11.6488', '-9.984', '-4.108', '-6.4785', '-4.6501', '1.6919', '-4.5543', '-4.8112', '-2.0736', '-5.296', '-5.7908', '-2.084', '-8.7672', '-2.0775', '-0.1021', '2.0387', '1.1266', '-1.782', '-7.3728', '-6.6934', '0.008', '0.165', '0.075', '0.124', '0.231', '0.359', '0.307', '0.249', '-0.115', '-0.276', '-0.156', '-0.147', '0.13', '-0.067', '0.268', '-0.071', '0.285', '0.529', '0.175', '-0.45', '0.403', '-0.191', '-0.022', '0.01', '0.028', '0.034', '0.017', '0.047', '0.04', '0.093', '0.093', '0.13', '0.084', '0.087', '0.04', '0.035', '0.039', '-0.007', '0.005', '-0.018', '-0.042', '-0.083', '0.011', '0.036', '-0.2', '-0.5', '-0.6', '-0.4', '-0.2', '-0.2', '0.3', '0.8', '0.9', '1.2', '0.9', '1', '1.2', '1.2', '1', '1.1', '0.7', '0.8', '0.4', '-0.5', '1.1', '1.3', '0.5', '-0.5', '-0.1', '0.3', '0.4', '0.8', '1.7', '0.9', '0.4', '1.7', '2.4', '1.8', '0.3', '1', '-0.1', '-2.8', '-2.8', '-5.1', '-0.6', '5', '-1.2', '0.1', '-0.8', '0.4', '0.3', '1.2', '3.3', '4.9', '5.8', '5.4', '3.1', '6.5', '6.2', '7.8', '6.7', '7.5', '6.6', '5.5', '5.2', '2.3', '0.3', '19.5', '4.6', '2.8', '0.3', '-0.6', '-0.8', '-0.3', '-0.2', '0.4', '1', '0.2', '0.1', '1.3', '3.7', '1.7', '0.6', '2.4', '1', '-0.6', '-1.1', '-2.7', '0.1', '5', '-0.4', '-0.7', '0.5', '0.5', '-1.3', '-0.1', '2.2', '1.2', '1.9', '1.8', '-2.4', '2.5', '1.5', '-0.4', '0.6', '-3.3', '-4.4', '-7.2', '-8.8', '-12.9', '-6.9', '2.5', '-2.2', '2.1', '0.2', '-2.4', '-2.2', '-2.8', '-4.3', '-4.8', '-5.4', '-8.1', '-9.2', '-7.7', '-4.7', '-5.5', '-10.3', '-2.7', '-5.3', '-7.9', '-9.5', '-11.2', '-5.5', '-9.5', '-6.5', '-3.4', '262', '251', '239', '213', '195', '185', '125', '63', '5', '4', '0', '1', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '0', '1', '0', '0', '0', '0', '0', '74.3', '74.5', '73.5', '74.5', '73.5', '73.6', '73.4', '74.4', '75.2', '74.3', '73.4', '74.1', '73.9', '75.2', '73.1', '73.4', '73.6', '90', '75.2', '119.7', '120', '120.2', '120.1', '119.1', '120.7', '120.2', '121.4', '121.4', '120.7', '119.9', '121.5', '121.7', '121.6', '120.6', '120.5', '118.2', '115.5', '123.3', '7.7', '23.2', '3.8', '20.3', '2.7', '8.3', '4.4', '6', '4.9', '9.4', '5.1', '9.1', '8.3', '11.9', '0', '10.8', '16.7', '33.3', '20', '0', '33.3', '0', '0', '50', '0', '50', '50', '0', '0', '100', '0', '0', '8', '14', '16', '19', '17', '26', '19', '21', '21', '5', '29', '10', '41.9', '45.3', '49.3', '49', '51.2', '58.4', '56.9', '64.9', '66.7', '62.4', '69.5', '74', '75.6', '78.5', '66.7', '65.5', '0', '193', '127.5', '123', '93.5', '95', '82.5', '86.5', '87.5', '76.5', '60', '47.5', '47', '50', '35', '32', '29', '50.5', '45', '37', '-9.77', '-15.58', '-27.5', '-30.12', '-34.22', '-34.92', '-38.58', '-54.46', '-54.39', '-64.43', '-64.04', '-64.91', '-74.74', '-78.15', '-79.1', '-72.38', '-77.6', '-66.67', '76', '80', '86', '85', '88.5', '90.5', '93', '94', '95', '99', '97', '99', '103', '103', '110', '110.5', '104', '103', '10', '13', '15', '15', '16', '15.5', '16', '16', '17', '18', '18', '18', '18', '19', '19', '20.5', '18', '22', '18', '10.91', '17.86', '18.64', '16.71', '24.26', '22.73', '32.43', '30.63', '33.93', '34.29', '35.71', '34.57', '36.11', '42.04', '36.97', '30.16', '39.05', '30.77', '40', '42.86', '47.73', '50', '46.15', '57.14', '58.33', '70.33', '65.15', '71.36', '57.14', '63.64', '62.5', '78.97', '69.74', '100', '75', '2.5', '21', '38.5', '40.8', '50', '41.3', '43.1', '37.1', '33.3', '38.6', '34.5', '42.6', '38.1', '39.5', '50', '58.3', '100', '41.2', '63.6', '60.6', '53.3', '74.2', '67.9', '88', '73.9', '73.9', '86.4', '77.3', '76.5', '78.6', '71.4', '75', '100', '64.3', '112.5', '68', '50', '37.5', '34', '31', '26', '27', '23', '22', '18.5', '21', '20', '20', '21', '17', '15.5', '7.5', '22', '17', '13', '12', '14', '13', '12', '12', '14', '14', '11', '11', '10.5', '10', '9', '8', '6.5', '5', '17.5', '9', '16', '13', '11', '13', '13', '12', '12', '13', '12', '10.5', '10', '9', '8', '9', '9', '9', '4', '16', '9', '95', '64', '37', '32.5', '27', '24', '12', '8', '5', '4', '3', '3', '3', '2', '2', '2', '1', '1', '3', '17', '30', '23', '17', '16', '13', '11', '10.5', '9', '8.5', '7', '7', '6', '6', '6', '5', '6', '2', '8', '88', '36', '25', '21', '17', '16', '14', '15', '12', '12.5', '11', '12', '13', '13', '12', '11.5', '12', '5.5', '13', '190', '131', '82', '74', '56', '31', '22', '13', '8', '6', '4', '4', '3', '3', '2', '1.5', '1', '0.5', '2', '41', '31', '24', '23', '20', '19', '16', '14', '7.5', '6', '6', '4', '4', '4.5', '4', '3', '2', '8', '5', '114', '69', '49', '37', '34', '30', '26', '25', '22', '19', '18', '19', '17.5', '18.5', '19', '16.5', '15', '7.5', '20', '-31.82', '-51.61', '-61.76', '-66.21', '-69.68', '-72.77', '-75.16', '-78.33', '-80.26', '-81.06', '-81.87', '-82.94', '-83.22', '-80.96', '-78.94', '-85.29', '-63.65', '-80.6', '-16.13', '-38.74', '-25', '-26.23', '-33.97', '-37.98', '-19.52', '-16.67', '-33.33', '-37.46', '-44.44', '-50', '-50', '-70.76', '-71.43', '-85', '210.98', '-50', '-32.29', '-40', '-27.05', '-30', '-37.5', '-40.54', '-29.41', '-29.29', '-44.6', '-45.65', '-62.5', '-62.5', '-47.5', '-58.33', '-62.07', '-84.62', '-79.4', '-51.42', '-32.49', '-61.11', '-66', '-70.64', '-78.57', '-88.89', '-93.14', '-94.17', '-96.25', '-96.75', '-96.53', '-97.96', '-98', '-98.46', '-98.64', '-98.68', '-96.15', '-96.83', '87.65', '42.86', '11.11', '-7.69', '-23.26', '-35.29', '-40', '-50', '-50', '-58.87', '-57.89', '-63.4', '-67.18', '-71.43', '-67.03', '-64.71', '-75.96', '-61.41', '-55.56', '-69.7', '-77.27', '-79.5', '-80.11', '-84.41', '-81.93', '-84.21', '-86.09', '-87.5', '-86.88', '-86.93', '-87.39', '-84.78', '-83.7', '-88.15', '-61.93', '-86.42', '-33.35', '-56.33', '-65.21', '-72.31', '-83.71', '-89.28', '-93.14', '-94.85', '-96.99', '-98.04', '-98.04', '-98.76', '-98.85', '-99.22', '-99.33', '-99.71', '-97.92', '-98.99', '-37.2', '-50', '-47.83', '-53.92', '-64.82', '-71.43', '-73.76', '-81.58', '-86.46', '-88.89', '-91.3', '-90.91', '-92.31', '-93.83', '-93.39', '-97.56', '-80.78', '-88.58', '-32.56', '-51.61', '-61.71', '-66.67', '-70.21', '-74.24', '-75.61', '-78.54', '-80.56', '-81.14', '-81.85', '-82.34', '-82.73', '-80.95', '-79.87', '-84.79', '-66.04', '-80.81', '5.7', '12.1', '18', '20.8', '22.6', '25.1', '30.2', '29.2', '2.47', '2.99', '2.54', '2.52', '2.22', '2.71', '3.19', '3.91', '3.41', '4.64', '5.93', '5.01', '6.12', '4.79', '7.7', '6.73', '9.7', '9.2', '10.97', '8.33', '10.88', '8.82', '14.48', '11.94', '5.66', '6.14', '8.84', '7.29', '9.19', '7.24', '8.71', '8.18', '4', '3.62', '2.34', '2.33', '1.78', '3.6', '4.39', '6.08', '6.34', '6.25', '7.85', '6.38', '7.62', '6.72', '11.25', '11.83', '4.96', '4.74', '3.73', '3.32', '3.61', '3.13', '3.27', '7.18', '8.91', '8', '10.05', '8.27', '10.86', '6.91', '13.53', '11.51', '7.61', '7.21', '9.59', '6.9', '8.16', '6.96', '10.32', '9.81', '8.87', '7.13', '8.17', '8.04', '8.23', '6.93', '11.69', '6.47', '4.91', '4.82', '4.85', '4.14', '4.81', '3.7', '5.74', '4.28', '50.4', '45.9', '44.4', '36.2', '40.3', '33.2', '26.1', '13.1']",['GlaxoSmithKline'],['GSK Clinical Trials'],['Study Director'],['Completed'],['Yes'],[],['Phase 3'],[],['GlaxoSmithKline'],['866-435-7343'],[],['GSK Response Center'],['March 2015'],['Actual'],"['An AE is defined as any untoward medical occurrence in a participant (par.) temporally associated with the use of a investigational product (IP), whether or not considered related to the IP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of an IP. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is an important medical event that jeopardizes the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition, or is associated with liver injury and impaired liver function. Only those participants available at the specified time points (represented by n=X, in the category titles) were analyzed.', 'AE rates by SOC adjusting for participant-years on study drug anytime post Baseline are summarized, which included the follow up visits. Only treatment-emergent adverse events (AEs) are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. The event rate of an AE was calculated as the number of events per 100 participant years: Event Rate = 100* Number of Events / Participant Years. Participant years were calculated as sum across all participants ([last visit of interval day - first visit of interval day + 1]/365). Participant years excluded between study gaps if participant had not started extension study on date of last visit of parent study.', 'SAE rates by SOC adjusting for participants-years on study drug anytime post Baseline are summarized, which included the follow up visits. Only treatment-emergent SAEs are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. The event rate of an SAE was calculated as the number of events per 100 participant years: Event Rate = 100* Number of Events / participants Years. participants years were calculated as = sum across all participants ([last visit of interval day - first visit of interval day + 1]/365). participants years excluded between study gaps if participant had not started extension study on date of last visit of parent study.', 'Hematology parameters were assessed at Baseline (BL) (Day 0), Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in APTT and PT is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'Hematology parameters were assessed at Baseline (BL) (Day 0), Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in basophils, eosinophils, lymphocytes, monocytes, neutrophils, neutrophils segmented and platelets is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'Hematology parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in erythrocytes is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'Hematology parameters were assessed at Baseline (BL) (Day 0), Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in hematocrit is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'Hematology parameters were assessed at Baseline (BL) (Day 0), Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in hemoglobin is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'Clinical chemistry parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in albumin and protein is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'Clinical chemistry parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in blood urea nitrogen, glucose, calcium, carbon dioxide, chloride, magnesium, phosphate, potassium and sodium is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'Clinical chemistry parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in urate, creatinine and bilirubin is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'Clinical chemistry parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in creatinine clearance is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'Clinical chemistry parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in BUN/creatinine is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'Clinical chemistry parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks and at exit visit. Change from Baseline in alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, gamma glutamyl transferase and lactate dehydrogenase is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'Immunogenic response was assessed by binding confirmatory assay at Baseline (BL) (Day 0), at Week 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Number of participants with the indicated immunogenic response are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Results of binding confirmatory assay were categorized as negative, persistent positive (defined as a positive immunogenic response that occurs at least 2 consecutive assessments or a single result at the final assessment) or transient positive (defined as a single positive immunogenic response that does not occur at the final assessment). Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'Systolic blood pressure (SBP) and diastolic blood pressure (DBP) was measured at Baseline (BL) (Day 0), at Week 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks and at exit visit. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'Serum creatinine was assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Percentage of participants with at least 25% increase from baseline in creatinine are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'Serum creatinine was assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Percentage of participants with at least 25% reduction from baseline in creatinine are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.']"
0,18,['NCT03973905'],[],[],['During the data collection period (from 1 January 2011 to 31 December 2014)'],"['72', '112', '5', '17', '72', '112', '1', '4', '1', '6', '27', '41', '72', '112', '6', '23', '49', '78', '1', '2', '0', '5', '3', '11', '16', '25']",['GlaxoSmithKline'],['GSK Clinical Trials'],['Study Director'],['Completed'],[],['No'],[],['GSKClinicalSupportHD@gsk.com'],['GlaxoSmithKline'],['866-435-7343'],[],['GSK Response Center'],"['May 15, 2019']",['Actual'],"['Vaccine effectiveness at preventing pertussis occurrence in infants < 2 months old is assessed by comparing the Boostrix immunization status during the third pregnancy trimester in mothers of infant pertussis cases and matched controls. The association between maternal Boostrix vaccination and pertussis in infants was analyzed using conditional logistic regression. The multivariate analysis was performed to obtain the adjusted values. Covariates that were statistically significant in the univariate analysis or considered as clinically significant were included in the multivariable conditional logistic regression model. Subjects with missing or unknown values, if any, for at least one of the risk factors were excluded from the model.']"
0,19,['NCT00340457'],[],[],[],[],['National Cancer Institute (NCI)'],"['Mark P Purdue, M.D.']",['Principal Investigator'],['Completed'],[],[],[],[],[],[],[],[],[],[],[]
0,20,['NCT02429284'],[],[],"['up to 5 years', 'up to 5 years', 'up to 5 years, at 6 month intervals']",[],"['University of California, San Diego']","['Kim M Kerr, MD']",['Principal Investigator'],['Completed'],['Yes'],['Yes'],[],[],[],[],[],[],['May 2019'],['Actual'],[]
0,21,['NCT02889263'],[],[],['30 days'],[],[],[],[],['Completed'],['No'],['No'],[],[],[],[],[],[],['September 2014'],['Actual'],[]
0,22,['NCT03995745'],[],[],['approximately 3 months after enrollment'],[],[],[],[],['Completed'],['No'],[],['Not Applicable'],[],[],[],[],[],"['September 27, 2019']",['Actual'],['viral load less than 400']
0,23,['NCT00928694'],[],"['35.1', '36.4', '1.61', '1.80']","['Predose and up to 168 hours postdose', 'Predose and up to 168 hours postdose']","['116', '121', '6.35', '6.48']",['Merck Sharp & Dohme Corp.'],['Medical Monitor'],['Study Director'],['Completed'],[],[],['Phase 1'],['ClinicalTrialsDisclosure@merck.com'],['Merck Sharp & Dohme Corp.'],['1-800-672-6372'],[],"['Senior Vice President, Global Clinical Development']",['April 2003'],['Actual'],[]
0,24,['NCT02153996'],[],[],['Five years'],[],['National Institute of Allergy and Infectious Diseases (NIAID)'],"['Eugene W Liu, M.D.']",['Principal Investigator'],['Terminated'],[],[],[],[],[],[],[],[],"['March 15, 2016']",['Actual'],[]
0,25,['NCT00413673'],[],[],['12 months after surgery'],[],['Walter Reed Army Medical Center'],"['KRAIG S. BOWER, MD']",['Principal Investigator'],['Completed'],[],[],['Not Applicable'],[],[],[],[],[],[],[],[]
0,26,['NCT03867409'],[],[],"['immediately after the intervention', 'immediately after the intervention', 'immediately after the intervention', 'immediately after the intervention', 'immediately after the intervention', 'immediately after the intervention', 'immediately after the intervention', 'immediately after the intervention', 'immediately after the intervention', 'immediately after the intervention', 'immediately after the intervention', 'immediately after the intervention', 'immediately after the intervention', 'immediately after the intervention', 'immediately after the intervention', 'immediately after the intervention', 'immediately after the intervention', 'immediately after the intervention', 'immediately after the intervention', 'immediately after the intervention', 'immediately after the intervention', 'immediately after the intervention']",[],['University of Florida'],"['Janice Krieger, PhD']",['Principal Investigator'],['Completed'],['Yes'],[],['Not Applicable'],[],[],[],[],[],"['March 14, 2019']",['Actual'],"['Perceived susceptibility (Birmingham et al., 2015) Please indicate how strongly you agree or disagree with the following statements (5=strongly agree; 1=strongly disagree).\n\nI am at risk for getting colon cancer in my lifetime.\nIt is possible that I will get colon cancer in my lifetime.\nI am susceptible to getting colon cancer in my lifetime.\nIt is likely that I will get colon cancer in my lifetime.', 'Perceived severity (Boonyasiriwat et al., 2013; Hsien Cheah, 2006; Lipkus & Klein, 2006) Please indicate how strongly you agree or disagree with the following statements (5=strongly agree; 1=strongly disagree).\n\n5. I believe that colon cancer is harmful. 6. I believe that colon cancer is a significant disease. 7. I believe that colon cancer has serious negative consequences. 8. I believe that colon cancer is serious. 9. I believe that colon cancer is dangerous. 10. I believe that colon cancer is life-threatening.', ""Perceived benefits (Christy et al., 2013; Purnell, Katz, Andersen, & Bennett, 2010; Rawl et al., 2001; Vernon, Myers, & Tilley, 1997) Please indicate how strongly you agree or disagree with the following statements (5=strongly agree; 1=strongly disagree).\n\n13. The FIT will decrease your chances of dying from colon cancer. 14. The FIT will help you not worry as much about colon cancer. 15. I believe that if I had a normal screening test result, I wouldn't have to worry about developing colon cancer.\n\n16. I believe that when colon cancer is found early, it can be cured."", 'Perceived barriers (Champion & Skinner, 2003; Gwede et al., 2011; James, Campbell, & Hudson, 2002) Please indicate how strongly you agree or disagree with the following statements (5=strongly agree; 1=strongly disagree).\n\n17. My doctor would never recommend the FIT. 18. The FIT would be too expensive. 19. The FIT would be too embarrassing. 20. Preparation for the FIT is too hard. 21. The FIT takes too much time. 22. The FIT is difficult because it is too hard to understand all the instructions.', 'Attitudes towards FIT/colonoscopy (Rydell, Sherman, Boucher, & Macy, 2012) Please indicate your feelings about FIT. Numbers 1 and 5 indicate a very strong feeling. Numbers 2 and 4 indicate a weak feeling. Number 3 indicates you are undecided.\n\nFIT is… 23. Awful-Nice 24. Unpleasant-Pleasant 25. Fun-Not Fun', 'Attitudes towards FIT/colonoscopy (Rydell, Sherman, Boucher, & Macy, 2012) Please indicate your feelings about colonoscopy. Numbers 1 and 5 indicate a very strong feeling. Numbers 2 and 4 indicate a weak feeling. Number 3 indicates you are undecided.\n\nColonoscopy is… 26. Awful-Nice 27. Unpleasant-Pleasant 28. Fun-Not Fun', 'Please indicate how strongly you agree or disagree with the following statements (5=strongly agree; 1=strongly disagree).\n\nI am confident that I can use the FIT. Arranging my schedule to use the FIT is an easy thing to do. FIT screening would be easy for me to do. It would be easy for me to take a stool sample. It would be easy for me to mail my kit back. It would be easy for me to use all the tools in the kit. I know how to collect a stool sample. I am confident that I can get a colonoscopy. Arranging my schedule to get a colonoscopy is an easy thing to do. Finding time to get a colonoscopy would be difficult for me to do. Screening for colon cancer with a colonoscopy would be easy for me to do. It would be easy for me to get a colonoscopy.', 'Response efficacy (Boer & Seydel, 1996; Duncan et al., 2014; Hwang et al., 2012, 2013; Vernon et al., 1997) Please indicate how strongly you agree or disagree with the following statements (5=strongly agree; 1=strongly disagree).\n\n7. FIT screening leads to early detection if something is wrong. 8. FIT screening leads to the detection of small abnormalities. 9. FIT screening will help me find cancer early. (What has Nick gotten from something like this?) 10. FIT screening will decrease my chances of dying from colon cancer', 'Comparative risk feedback (Dillard, Ferrer, Ubel, & Fagerlin, 2012; Weinstein et al., 2004) 11. Compared to the average person-your age, gender, and race-how would you rate your chances of developing colon cancer in your life? (Very much higher, much higher, higher, average, lower, much lower, very much lower)', ""Cancer Information Overload (Jensen, Carcioppolo, et al., 2014) Below are some statements about the information you read and hear about cancer. For each statement, please indicate how strongly you agree or disagree with the following statements (5=strongly agree; 1=strongly disagree).\n\n12. There are so many different recommendations about preventing cancer, it's hard to know which ones to follow.\n\n13. There is not enough time to do all of the things recommended to prevent cancer.\n\n14. It has gotten to the point where I don't even care to hear new information about cancer.\n\n15. I feel overwhelmed by the amount of cancer information I am supposed to know."", 'Cancer fatalism (Powe, 1995; Shen, Condit, & Wright, 2009) Please indicate how strongly you agree or disagree with the following statements (5=strongly agree; 1=strongly disagree).\n\n11. I will die if I get colon cancer. 12. If I am diagnosed with colon cancer, I have little chance of surviving the disease.', 'Perceived Message Relevance Scale (Jensen, King, et al., 2014; Jensen, King, Carcioppolo, & Davis, 2012) Please indicate how strongly you agree or disagree with the following statements (5=strongly agree; 1=strongly disagree).\n\n16. The message seemed to be written personally for me. 17. The message was very relevant to my situation. 18. The message was applicable to me. 19. The message was very customized to me. 20. This message was manipulative. 21. This message was misleading.', 'Argument strength (Zhao, Strasser, Cappella, Lerman, & Fishbein, 2011) Please indicate how strongly you agree or disagree with the following statements (5=strongly agree; 1=strongly disagree) about colon cancer screening.\n\n22. The visit is a reason for screening with FIT that is believable. 23. The visit is a reason for screening with FIT that is convincing. 24. The visit is gives me a reason for screening with FIT that is important to me.\n\n25. The visit helped me feel confident about how best to screen with FIT. 26. The visit would help my friends screen with FIT. 27. The visit put thoughts in my mind about wanting to screen with FIT. 28. The statement put thoughts in my mind about not wanting to avoid screening. 29. Overall, how much do you agree or disagree with the visit? 30. Is the reason the visit gave for screening with FIT a strong reason or weak reason?', ""Source credibility (McCroskey & Teven, 1999) Please indicate your feelings about Alex. Numbers 1 and 5 indicate a very strong feeling. Numbers 2 and 4 indicate a weak feeling. Number 3 indicates you are undecided.\n\n37. Intelligent-Unintelligent 38. Trained-Untrained 39. Cares about me-Doesn't care about me 40. Honest-Dishonest 41. Has my interests at heart-Doesn't have my interests at heart 42. Trustworthy-Untrustworthy 43. Expert-Inexpert 44. Not self-centered-Self-centered 45. Concerned with me-Not concerned with me 46. Honorable-Dishonorable 47. Informed-Uninformed 48. Moral-Immoral 49. Competent-Incompetent 50. Ethical-Unethical 51. Sensitive-Insensitive 52. Bright-Stupid 53. Genuine-Phony 54. Understanding-Not understanding"", ""Please indicate how strongly you agree or disagree with the following statements (5=strongly agree; 1=strongly disagree).\n\nI doubt that my doctor really cares about me as a person. My doctor usually puts my needs first. I trust my doctor so much I always try to follow his/her advice. If my doctor tells me something is so, then it must be true. I sometimes distrust my doctor's opinion. I trust my doctor's judgments about my medical care. I feel my doctor does not do everything he/she should about my medical care. I trust my doctor to put my medical needs above all other considerations when treating my medical problems.\n\nMy doctor is well qualified to manage (diagnose and treat or make an appropriate referral) medical problems like mine.\n\nI trust my doctor to tell me if a mistake was made about my treatment. I sometimes worry that my doctor may not keep the information we discuss totally private."", ""Patient-provider communication scale (Katz et al., 2004) Please indicate how strongly you agree or disagree with the following statements (5=strongly agree; 1=strongly disagree).\n\n66. I receive enough understandable information from my doctor/healthcare provider to make good decisions about my health.\n\n67. I feel rushed during visits. 68. My doctor/healthcare provider involves me in decisions about my health care treatment.\n\n69. I feel uncomfortable asking my doctor for tests or information if he/she doesn't mention it.\n\n70. My doctor/healthcare provider understands my health needs."", 'Patient general health (SF-36) (Fan, Burman, McDonell, & Fihn, 2005; Jenkinson, Coulter, & Wright, 1993; RAND Corporation, n.d.) 71. In general, would you say your health is:\n\nExcellent\nVery good\nGood\nFair\nPoor 72. How much bodily pain have you had during the past 4 weeks?\nNone\nVery mild\nMild\nModerate\nSevere\nVery severe 73. During the past 4 weeks, how much did pain interfere with your normal work (including both work outside the home and housework)?\nNot at all\nA little bit\nModerately\nQuite a bit\nExtremely', 'eHeals Health Literacy (Norman & Skinner, 2006) Please indicate how strongly you agree or disagree with the following statements (5=strongly agree; 1=strongly disagree).\n\n74. I know how to find helpful health resources on the Internet. 75. I know how to use the Internet to answer my health questions. 76. I know what health resources are available on the Internet. 77. I know where to find helpful health resources on the Internet. 78. I know how to use the health information I find on the Internet to help me. 79. I have the skills I need to evaluate the health resources I find on the Internet.\n\n80. I can tell high quality from low quality health resources on the Internet. 81. I feel confident in using information from the Internet to make health decisions.', 'Transportation (Green & Brock, 2000) Please indicate how strongly you agree or disagree with the following statements (5=strongly agree; 1=strongly disagree).\n\n82. During the appointment, I could easily picture myself in the exam room. 83. While I was reading the narrative, activity going on in the room around me was not on my mind.\n\n84. I could picture myself in the scene of the events described in the narrative.\n\n85. I was mentally involved in the conversation while reading it. 86. After finishing the appointment, I found it easy to put it out of my mind. 87. I wanted to learn how the narrative ended. 88. The appointment affected me emotionally. 89. I found myself thinking of ways the narrative could have turned out differently.\n\n90. I found my mind wandering while reading the narrative. 91. The events in the narrative are relevant to my everyday life. 92. The events in the narrative have changed my life.', 'In the last 12 months, how often have you used a secure website or application (""app"") to track your health information online?\n\nDaily\nWeekly\nMonthly\nA few times a year\nI don\'t use websites or applications for this. What device(s) do you use to access your personal health information online? (Please circle all that apply)\nPhone\nTablet\nLaptop/desktop Please indicate how strongly you agree or disagree with the following statements (5=strongly agree; 1=strongly disagree).\n\n-Various statements about PHI, electronic storage, and access-\n\nPlease rate how similar you are to Alex on the following dimensions:\n\nGender Race Age Please indicate how strongly you agree or disagree with the following statements (5=strongly agree; 1=strongly disagree).\n\n-Various questions about the virtual assistant\'s usefulness-', ""Homophily (Lin & Guan, 2003; McCroskey, Richmond, & Daly, 1975; Z. Wang, Walther, Pingree, & Hawkins, 2008) Alex, my healthcare assistant… 129. Thinks like me-doesn't think like me 130. Behaves like me-doesn't behave like me 131. Is similar to me-is different from me 132. Is like me-is unlike me 133. Has a background similar from mine-has a background different to mine 134. Has morals like mine-has morals unlike mine 135. Looks similar to me-looks different from me 136. Has the same body size as I do-is a different body size than I am"", 'Interpersonal Distance (Bailenson, Blascovich, Beall, & Loomis, 2003) Please indicate how strongly you agree or disagree with the following statements (5=strongly agree; 1=strongly disagree).\n\n137. I perceive that I am in the presence of Alex in the room with me. 138. I feel that Alex is aware of my presence. 139. The thought that Alex is not a real person crosses my mind often. 140. I perceive Alex as being only a computerized image, not as a real person.']"
0,27,['NCT04004260'],[],[],['8 weeks [Baseline; 2 month (last treatment session)]'],[],['Lamar University'],"['Vinaya Manchaiah, PhD']",['Principal Investigator'],"['Active, not recruiting']",['Yes'],[],['Not Applicable'],[],[],[],[],[],"['August 31, 2021']",['Anticipated'],"['The TFI is a 25-item questionnaire that evaluates treatment responsiveness (i.e., changes in functional effects of tinnitus over time). Total possible score ranges from 0-to-100 (scores >25 indicate tinnitus is a significant problem).']"
0,28,['NCT04205877'],[],[],"['6 months', '6 months', '6 months', '6 months', '6 months']",[],['National Principal Investigator'],"['Shyam Sathanandam, MD']",['Principal Investigator'],['Not yet recruiting'],['No'],['No'],[],[],[],[],[],[],"['January 1, 2030']",['Anticipated'],"['Access vessel complications include femoral arterial or femoral/jugular venous complications noted during the procedure, immediately after the procedure or delayed (>24 hours). They range from bleeding from access sites, arterial or venous thrombosis with or without the need for treatment to loss of limb secondary to arterial occlusion.', 'Valvular injury includes damage to the tricuspid valve or other cardiac valve resulting in immediate post-procedural valvular dysfunction.', 'Device embolization includes malposition of the device either during or after the procedure or delayed (>24 hours). The outcome of device embolization ranges from observation, transcatheter retrieval at time of procedure or at a separate time, surgical retrieval, other end organ damage, to mortality.', 'Adjacent vessel stenosis includes a narrowing of the aorta or the left pulmonary artery directly as a consequence of device implantation for PDA closure. Vessel stenosis could happen either during or after the procedure or delayed (>24 hours). The outcome of vessel stenosis ranges from no intervention needed to repeated transcatheter and surgical therapies.', 'The effectiveness endpoint is the rate of effective closure of the PDA using a transcatheter device within six months post procedure. If more than one attempt is required, or multiple devices are required during the same procedure, it is still considered effective if there is Grade 0 or Grade 1 shunt, as defined below, at follow-up by transthoracic echocardiography or if a second procedure is not required following the initial attempt. If there is device embolization, adjacent vessel stenosis that required retrieval of the device and replacement during the same procedure with less than Grade 1 shunt during follow-up, it is still considered effective. Conversely, if an AE is noted after the procedure that requires a second procedure for treatment that results in greater than Grade 1 shunt, then the procedure is considered not effective, even if the initial attempt was effective. See protocol for PDA shunt definitions.']"
0,29,['NCT01262079'],[],[],['2010-2011 influenza season'],[],['Chief: Clinical Trials Core'],"['Barney S. Graham, M.D., Ph.D.']",['Study Director'],['Completed'],['No'],[],[],[],[],[],[],[],['July 2011'],['Actual'],['To evaluate antibody responses to a panel of influenza strains across a broad age range of the U.S. population early as compared to late in the 2010-2011 influenza season.']
0,30,['NCT00646438'],[],[],['3 years'],[],['Providence Heart & Vascular Institute'],"['Anthony Furnary, MD']",['Principal Investigator'],['Unknown status'],['No'],[],['Not Applicable'],[],[],[],[],[],['February 2012'],['Anticipated'],[]
0,31,['NCT00341588'],[],[],['16 years'],[],['National Cancer Institute (NCI)'],"['Katherine A McGlynn, Ph.D.']",['Principal Investigator'],['Completed'],[],[],[],[],[],[],[],[],"['October 1, 2008']",['Actual'],[]
0,32,['NCT04562636'],[],[],['~10 minute computer survey immediately after seeing messages'],[],"['University of North Carolina, Chapel Hill', 'University of North Carolina, Chapel Hill']","['Hannah Rayala', 'Lindsey Smith Taillie, PhD']","['Principal Investigator', 'Study Chair']",['Completed'],['No'],[],['Not Applicable'],[],[],[],[],[],"['October 1, 2020']",['Actual'],"['Perceived effectiveness of the messages will be measured during the message using 4 items adapted from Baig et al. (2018): concern, unpleasantness, and discouragement. The averaged responses on the 4 items will be used to create a PME score. All 4 items are measured using a a 1 to 5 likert scale, with higher scores representing a higher amount of the construct.\n\nQuestions: How much do these messages...\n\nmake you concerned about the health effects of eating red meat?\nmake you concerned about the environmental effects of eating red meat?\ndiscourage you from wanting to eat red meat?\n\nmake eating red meat seem unpleasant to you?\n\nNot at all, 2=Very little, 3=Somewhat, 4=Quite a bit, 5=A great deal).']"
0,33,['NCT03924505'],[],[],"['Baseline', '12 months', 'Baseline', '12 months', 'Baseline', '12 months']",[],['RTI International'],"['Barrot Lambdin, PhD, MPH']",['Principal Investigator'],['Recruiting'],['No'],[],['Not Applicable'],[],[],[],[],[],['September 2021'],['Anticipated'],"['Number of Best Practices adopted by the SSP', 'Number of Best Practices adopted by the SSP', 'Number of SSP participants receiving a dose of naloxone', 'Number of SSP participants receiving a dose of naloxone', 'Naloxone Dispensed', 'Naloxone Dispensed']"
0,34,['NCT02334462'],[],[],"['U.S. Study: Days 1,3,7,14,28,29,31,35,42,56,84,112,140,168 and 196. Same as U.S. plus Days 169,171,175,182,189,196,203,210,217,240,2 70,300,330,360,390,420,450,480,510,540,541,543,547,554,561,568,575,582,589,610,640,670,700,730']",[],['National Institute of Allergy and Infectious Diseases (NIAID)'],"['Patrick E Duffy, M.D.']",['Principal Investigator'],['Completed'],[],[],['Phase 1'],[],[],[],[],[],"['March 31, 2016']",['Actual'],[]
0,35,['NCT03311295'],[],[],"['30 days post procedure', 'Baseline to 1 year']",[],['University California Davis'],"['Reginald Low, MD']",['Principal Investigator'],['Recruiting'],['Yes'],[],['Not Applicable'],[],[],[],[],[],"['April 3, 2021']",['Anticipated'],"['Major Adverse Events (MAEs) will be categorized and defined in accordance with the relation to the procedure and device.', 'Mitral regurgitation grade by ASE criteria and change from baseline to 1 year evaluated by 2-D transthoracic echocardiogram']"
0,36,['NCT03242278'],[],[],"['At baseline', 'At baseline']",[],['Bayer'],['Bayer Study Director'],['Study Director'],['Completed'],['No'],['No'],[],[],[],[],[],[],"['March 1, 2016']",['Actual'],[]
0,37,['NCT03683134'],[],[],"['Change from at baseline blood pressure to 6-weeks', 'Change from at baseline blood pressure to 12-weeks']",[],"['Auburn University', 'Auburn University']","['Michael W Greene, PhD', 'Amy W Willis, MS, RD']","['Study Chair', 'Principal Investigator']",['Completed'],['No'],[],['Not Applicable'],[],[],[],[],[],"['September 7, 2017']",['Actual'],"['Measured in mmHg', 'Measured in mmHg']"
0,38,['NCT04047316'],[],[],"['6 months', '1 month', '1 year']",[],[],[],[],['Completed'],[],['No'],[],[],[],[],[],[],"['April 15, 2020']",['Actual'],"['The outcome will be measured by a questionnaire with performance-related questions for clinicians to answer about a set of images from the collected database. A Likert-based scale will be used for the answers: from highly agree to highly disagree.', 'The outcome will be measured by a questionnaire with usability-related questions for clinicians.', 'The number of adverse events will be reported to assess safety of the device.']"
0,39,['NCT03952364'],[],[],['12 month follow up'],[],['PredictImmune Ltd'],"['James Lee, MD']",['Principal Investigator'],['Recruiting'],['Yes'],['No'],[],[],[],[],[],[],['June 2021'],['Anticipated'],['Stratifying patients into high or low risk of following an aggressive disease course requiring frequent treatment escalations.']
0,40,['NCT04021030'],[],[],['3 months post-intervention'],[],['University of Michigan'],"['Mark Ilgen, Ph.D.']",['Principal Investigator'],"['Active, not recruiting']",[],[],['Not Applicable'],[],[],[],[],[],"['December 31, 2020']",['Anticipated'],"['Pain level will be assessed using the Numeric Rating Scale (NRS). The NRS is a 0-10 scale, with higher scores indicating greater intensity of pain.']"
0,41,['NCT02959827'],['11.2'],[],['In the 365 days post exposure to an iodinated contrast agent'],"['15.9', '4', '193', '6', '168', '6', '168', '4', '253', '14', '1504', '24', '1264', '10', '1022', '4', '300', '3', '320', '9', '297', '2', '260', '2', '266', '4', '263', '4', '234', '6', '241', '0', '105', '18', '1762', '16', '528', '13', '787', '4', '170', '6', '720', '9', '416', '2', '193', '4', '3', '4', '3', '10', '10', '15', '9', '2', '1', '1', '6', '23', '11']",[],[],[],['Completed'],['No'],['No'],[],['clinical-trials-contact@bayer.com'],['Bayer'],['(+) 1-888-8422937'],[],['Therapeutic Area Head'],"['June 15, 2017']",['Actual'],['Incidence density rates (IDR) were calculated as the number of cases over the person time at risk where the numerator was the number of cases and the denominator was the person years at risk.']
0,42,['NCT02395536'],[],[],['3 Months post insertion'],"['2', '2']",[],[],[],['Completed'],['No'],[],['Not Applicable'],['lindsay.k.werder@medtronic.com'],"['Medtronic, PLC']",['7635268168'],[],"['Lindsay Werder, Senior Clinical Research Specialist']","['May 31, 2016']",['Actual'],"['Demonstrate that the untoward event rate associated with Reveal LINQ™ insertions performed in-office or in the traditional hospital setting (operating room, cardiac catheterization or EP laboratory) are comparable.\n\nUntoward events are a composite of unsuccessful Reveal LINQ™ or complications related to the Reveal LINQ™ insertion procedure or system.']"
0,43,['NCT03628235'],[],[],"['12 months', '12 months', '12 months', '12 months']",[],[],[],[],['Recruiting'],['No'],['No'],[],[],[],[],[],[],"['December 31, 2021']",['Anticipated'],"[""Productivity loss is measured by annual lost wages and it is collected in the survey's employment questionnaires and WPAI"", 'The indirect costs associated with the total annual out-of-pocket expenses.', 'The total informal care time received during a typical week', 'The indirect costs associated with the annual opportunity costs of companion']"
0,44,['NCT02787538'],[],[],['Change measure (baseline score compared to after using the US-ANSWER-2 intervention at Month 1)'],[],['Massachusetts General Hospital'],"['Hyon K Choi, MD, DrPH']",['Principal Investigator'],['Unknown status'],['No'],[],['Not Applicable'],[],[],[],[],[],['December 2017'],['Anticipated'],"['The Decisional Conflict Scale (short version) measures personal perceptions of uncertainty in choosing options, factors contributing to uncertainty, and effective decision-making. It is one-dimensional and has 10 questions and three response categories (yes/no/unsure) used to compute one score.']"
0,45,['NCT01290393'],[],[],['This outcome measure will be recorded between zero and six weeks after end of pregnancy'],[],['GlaxoSmithKline'],['GSK Clinical Trials'],['Study Director'],['Terminated'],[],[],[],[],[],[],[],[],"['December 20, 2012']",['Actual'],[]
0,46,['NCT04263311'],[],[],"['Baseline Visit, 6 months visits']",[],['NYU Langone'],['Nadia Islam'],['Principal Investigator'],['Recruiting'],['No'],[],['Not Applicable'],[],[],[],[],[],['June 2021'],['Anticipated'],['The primary outcome will be the proportion of eligible patients at a practice site to achieve BP control (130/80 mmHg) six months following the index office visit. Individuals receiving care during the implementation of the intervention will be more likely achieve BP control six months following the index office visit than individuals receiving care as usual. The primary outcome of interest is the proportion of patients who achieve BP control. this will be measured by the treatment participants and providers surveys.']
0,47,['NCT00875641'],"['0.006', '0.012', '0.010', '0.006', '0.003', '0.006', '0.000', '0.015', '0.009', '0.000', '0.000', '0.000', '0.000', '0.000', '0.000', '0.000', '0.001', '0.000', '0.000', '0.011', '0.008', '0.000', '0.000', '0.004', '0.001', '0.019', '0.005', '0.000', '0.003', '0.003', '0.000', '0.001', '0.004', '0.000', '0.002', '0.000', '0.166', '0.113', '0.116', '0.166', '0.086', '0.087', '0.115', '0.121', '0.125', '1.346', '1.230', '1.561', '1.459', '1.397', '1.848', '1.042', '0.961', '1.123', '0.955', '0.725', '1.135', '1.280', '0.870', '1.497', '0.228', '0.401', '0.491', '1.351', '1.255', '1.634', '1.518', '1.341', '1.939', '0.911', '1.048', '1.132', '0.022', '0.030', '0.043', '0.015', '0.036', '0.047', '0.014', '0.012', '0.023']",[],"['60 days following each vaccination', '7 days following each vaccination', '30 days following each vaccination']","['0.021', '0.022', '0.021', '0.028', '0.012', '0.017', '0.013', '0.032', '0.025', '0.000', '0.014', '0.000', '0.000', '0.000', '0.000', '0.000', '0.029', '0.000', '0.010', '0.026', '0.022', '0.000', '0.006', '0.020', '0.025', '0.048', '0.024', '0.000', '0.008', '0.009', '0.000', '0.006', '0.014', '0.000', '0.011', '0.004', '0.230', '0.142', '0.146', '0.252', '0.121', '0.124', '0.200', '0.165', '0.174', '1.518', '1.320', '1.669', '1.696', '1.529', '2.008', '1.278', '1.079', '1.260', '1.397', '0.932', '1.406', '1.960', '1.184', '1.921', '0.622', '0.641', '0.774', '1.593', '1.383', '1.788', '1.858', '1.523', '2.166', '1.228', '1.221', '1.327', '0.048', '0.045', '0.062', '0.047', '0.059', '0.075', '0.050', '0.029', '0.045']",['GlaxoSmithKline'],['GSK Clinical Trials'],['Study Director'],['Completed'],[],[],[],[],['GlaxoSmithKline'],['866-435-7343'],[],['GSK Response Center'],"['November 4, 2016']",['Actual'],"['Incidence rates were calculated following the first 2 doses of study vaccine as the number of events divided by the sum of the person-time in that risk period. Person-time was defined as the number of days at risk for the study outcomes. Person-time was calculated in months by dividing the number of person-days by (365.25/12).', 'Incidence rates were calculated following the first 2 doses of study vaccine as the number of events divided by the sum of the person-time in that risk period. Person-time was defined as the number of days at risk for the study outcomes. Person-time was calculated in months by dividing the number of person-days by (365.25/12).', 'Incidence rates were calculated following the first 2 doses of study vaccine as the number of events divided by the sum of the person-time in that risk period. Person-time was defined as the number of days at risk for the study outcomes. Person-time was calculated in months by dividing the number of person-days by (365.25/12).']"
0,48,['NCT03199846'],[],[],['Aproximately 6 months'],[],['Bristol-Myers Squibb'],['Bristol-Myers Squibb'],['Study Director'],['Completed'],['No'],['No'],[],[],[],[],[],[],"['October 30, 2017']",['Actual'],"['Distribution of treatment patterns for advanced melanoma patients including, treatment regimen selection and rationale, as well as time to initiation of therapy and type of therapy']"
0,49,['NCT04587245'],[],[],['12 months'],[],['University of California Irvine Beall Applied Innovation'],"['Henry Broeska, PhD']",['Principal Investigator'],['Recruiting'],['No'],['No'],[],[],[],[],[],[],"['October 15, 2021']",['Anticipated'],"['Change in monthly income of healthcare Providers from baseline to 6, 9 and 12 months after the beginning of the COVID-related events']"
0,50,['NCT02773979'],[],[],"['Days 1-203', 'Days 1-93', 'Day 1-116', 'Days 1-130', 'Day 1-93', 'Day 1-116', 'Days 1-130']",[],[],[],[],['Completed'],[],[],['Phase 1'],[],[],[],[],[],"['January 22, 2018']",['Actual'],[]
0,51,['NCT03274726'],[],[],['1999-2010'],[],[],[],[],['Completed'],[],['No'],[],[],[],[],[],[],"['December 1, 2010']",['Actual'],['Total Body Iron <0 mg/kg']
0,52,['NCT01283828'],[],[],['2 years'],[],['Gynuity Health Projects'],"['Beverly Winikoff, M.D., M.P.H.']",['Principal Investigator'],['Completed'],['Yes'],[],[],[],[],[],[],[],['April 2013'],['Actual'],[]
0,53,['NCT04191824'],[],[],['Baseline to 3 month study visit'],[],['Duke University'],['Hrishikesh Chakraborty'],['Principal Investigator'],['Recruiting'],['Yes'],[],['Not Applicable'],[],[],[],[],[],"['April 15, 2022']",['Anticipated'],['Change in systolic blood pressure']
0,54,['NCT03197688'],[],[],"['Observation period from 19 Oct 2013 to 31 March 2017, Data collection from 1 Apr 2017 to 30 Jun 2018']",[],[],[],[],['Completed'],['No'],['No'],[],[],[],[],[],[],"['September 6, 2018']",['Actual'],"['Incidence rates of liver test abnormalities, Occurrence of Hepatic Adverse Events (HAEs), Occurrence of any other Adverse Event (AE), Occurrence and reason for discontinuation of Opsumit treatment, hospitalization and death']"
0,55,['NCT02813577'],[],[],"['12 months post index procedure', '12 months post index procedure']","['0', '0']",['Wellmont CVA Heart Institute'],"['Christopher Metzger, MD']",['Principal Investigator'],['Terminated'],['No'],[],['Not Applicable'],['anna.lovas@bd.com'],['Becton Dickinson'],['763-445-2385'],[],['Anna Lovas'],"['February 18, 2019']",['Actual'],"['Index limb amputation includes above or below the ankle amputations.', 'Primary patency is defined as freedom from target lesion restenosis (TLR) and from binary restenosis. Binary restenosis is adjudicated by the independent Core Laboratory based on Peak Systolic Velocity Ratio (PSVR) ≥ 2.5 and / or abnormal waveforms, or based on angiographic ≥ 50% diameter stenosis.']"
0,56,['NCT00666380'],[],[],"['7 days', '30 days', '1 year']",[],"['Walter Reed Army Institute of Research (WRAIR)', 'Kenya Medical Research Institute']","['Michele D Spring, MD, M.S.P.H.', 'Nekoye N. Otsyula, M.B. Ch. B.']","['Principal Investigator', 'Principal Investigator']",['Completed'],['Yes'],[],['Phase 1'],[],[],[],[],[],['December 2008'],['Actual'],"['Occurrence and intensity of solicited symptoms on day of vaccination and Days 1-7 after each vaccination', 'Occurrence and intensity of unsolicited symptoms over a 30-day follow-up period (day of vaccination and 29 subsequent days) after each vaccination']"
0,57,['NCT01287247'],[],[],['Two treatment cycles (approximately 6 months/subject)'],[],['Center for Neurological Restoration'],"['Hubert H. Fernandez, MD, FAAN']",['Principal Investigator'],['Completed'],['No'],[],[],[],[],[],[],[],['April 2013'],['Actual'],"['To collect, evaluate and report observational data about the clinical use of Xeomin® in a ""real world"" setting to determine injection patterns and use of guidance techniques.']"
0,58,['NCT04163341'],[],[],"['Duration of recruitment phase (9 months)', 'At treatment exit (approximately 3 months post-baseline)', ""At each CETA treatment session, over the approximately 3 months of each client's CETA treatment""]",[],"['UNC-Chapel Hill', 'UNC-Chapel Hill', 'University of Washington']","['Brian Pence, PhD', 'Bradley Gaynes, MD', 'Doyane Darnell, PhD']","['Principal Investigator', 'Principal Investigator', 'Principal Investigator']",['Not yet recruiting'],['No'],[],['Not Applicable'],[],[],[],[],[],['November 2021'],['Anticipated'],"['Number of patients approached in order to accrue the final sample', 'Client Satisfaction Questionnaire-8', 'Counselor adherence to CETA content and skill in delivery will be rated by supervisor based on review of audiorecordings of a subset of sessions']"
0,59,['NCT02987335'],[],[],"['0 min to 360 min', '0 min to 360 min', '0 min to 360 min', '0 min to 360 min']",[],['Albert Einstein College of Medicine'],['Meredith Hawkins'],['Principal Investigator'],['Not yet recruiting'],['Yes'],['No'],[],[],[],[],[],[],['December 2022'],['Anticipated'],"['Measurements of plasma insulin, C-peptide, glucagon, and GH are taken throughout the study in order to evaluate the adequacy of the pancreatic clamp technique, i.e. the inhibitory effects of somatostatin on hormone secretion and the uniformity of hormone replacement.', 'Measurements of plasma insulin, C-peptide, glucagon, and GH are taken throughout the study in order to evaluate the adequacy of the pancreatic clamp technique, i.e. the inhibitory effects of somatostatin on hormone secretion and the uniformity of hormone replacement.', 'Measurements of plasma insulin, C-peptide, glucagon, and GH are taken throughout the study in order to evaluate the adequacy of the pancreatic clamp technique, i.e. the inhibitory effects of somatostatin on hormone secretion and the uniformity of hormone replacement.', 'Measurements of plasma insulin, C-peptide, glucagon, and GH are taken throughout the study in order to evaluate the adequacy of the pancreatic clamp technique, i.e. the inhibitory effects of somatostatin on hormone secretion and the uniformity of hormone replacement.']"
0,60,['NCT02867722'],[],[],['1 year and 5 years'],[],"[""Brigham and Women's Hospital""]","['Emily Stamell Ruiz, MD']",['Principal Investigator'],['Not yet recruiting'],['Yes'],[],['Not Applicable'],[],[],[],[],[],['December 2021'],['Anticipated'],[]
0,61,['NCT03276637'],[],[],"['Baseline, after education (within 1 month of baseline), 6 months prior to study completion', 'Baseline, 6 weeks after results disclosure', 'Results disclosure (within 1 month of sequencing completion)', 'Within 2 weeks after results disclosure for military healthcare provider-participants, 6 weeks after results disclosure for active-duty patient-participants, 1 year after results disclosure']",[],[],[],[],"['Active, not recruiting']",['Yes'],[],['Not Applicable'],[],[],[],[],[],"['December 31, 2019']",['Anticipated'],"[""Novel and adapted (Kaphingst, K.A., et al. 2012; Bowling, B.V., et al. 2008) survey measures will assess military healthcare providers' genomic knowledge before and after receiving a genomic education primer, and after disclosing one or more whole exome sequencing result(s)"", ""Novel survey measures will assess active-duty patient-participants' perceptions of military health system integration of genomic data on career status"", 'Whole exome sequencing results will identify the counts and proportions of genomic findings in the active-duty patient-participant population', 'Novel survey measures and military medical record review by trained genetic professional(s) will assess the percentage of active-duty patient-participants who receive follow-up recommendations and healthcare interventions, as well as their appropriateness']"
0,62,['NCT03192891'],[],[],"['from time of study to the date 4 years following', 'from time of study to the date 4 years following', 'from time of study to the date 4 years following']",[],[],[],[],"['Active, not recruiting']",['No'],['No'],[],[],[],[],[],[],"['March 31, 2018']",['Actual'],"['all-cause mortality', 'Acute Myocardial Infarction', 'PCI or CABG beyond 60 days after CMR']"
0,63,['NCT03373045'],[],[],"['At baseline, every 6 months, through study completion, assessed up to 7 years.', 'At baseline, every 6 months, through study completion, assessed up to 7 years.', 'At baseline, every 1 month, through study completion, assessed up to 7 years.', 'Change from baseline, every 1 month, through study completion, assessed up to 7 years.', 'Change from baseline, every 1 month, through study completion, assessed up to 7 years.', 'At baseline, every 3 months, through study completion, assessed up to 7 years.', 'At baseline, every 6 months, through study completion, assessed up to 7 years.', 'At baseline, every 6 months, through study completion, assessed maximum up to 7 years.', 'At baseline, every 6 months, through study completion, assessed up to 7 years.', 'At baseline, every 6 months, through study completion,assessed up to 7 years.', 'At baseline, every 6 months, through study completion, assessed up to 7 years.', 'At baseline, every 6 months, through study completion, assessed up to 7 years.', 'At baseline, every 6 months, through study completion, assessed up to 7 years.', 'Change from baseline, every 6 months, through study completion, assessed up to 7 years.', 'Change from baseline, every 6 months, through study completion, assessed up to 7 years.', 'Change from baseline, every 6 months, through study completion, assessed up to 7 years.', 'Change from baseline, every 6 months, through study completion, assessed up to 7 years.', 'Change from baseline, every 6 months, through study completion, assessed up to 7 years.', 'Change from baseline, every 6 months, through study completion, assessed up to 7 years.']",[],[],[],[],['Recruiting'],['No'],['Yes'],[],[],[],[],[],[],"['January 31, 2026']",['Anticipated'],"[""Longitudinal changes of Healthcare utilization will be measured using directly collected information from medical, hospital, and pharmacy records to provide a supplementary comprehensive assessment of each patient's healthcare utilization during the study period."", 'Asthma medications with dose and start/stop dates including all FDA-approved and standard of care treatments for asthma will be assessed. Longitudinal changes in asthma treatment will also be assessed.', ""Extraction of electronic medical, hospital, and pharmacy records will take place at study close and potentially at interim time points to provide a supplementary assessment of each patient's healthcare resource utilization. Longitudinal changes in patient reported treatment adherence will also be assessed."", 'Patient-reported asthma symptoms and control will be collected via the ACT questionnaire; a 5 item, self-administered survey that is designed to help the patient describe their asthma and how it affects their daily activities. ACT questionnaire is a 5-point scale (for symptoms and activities: 1=all the time to 5= not at all; for asthma control rating: 1=not controlled at all to 5=completely controlled).', 'Asthma exacerbations, the primary analytical definition will be worsening of asthma that leads to any of the following: Use of systemic corticosteroids (or a temporary increase in a stable corticosteroid background dose) for at least 3 days; a single depo-injectable dose of corticosteroids will be considered equivalent to a 3-day course of systemic corticosteroids. An emergency department or urgent care visit (defined as evaluation and treatment for <24 hours in an emergency department or urgent care center) due to asthma that required systemic corticosteroids. An inpatient hospitalization (defined as admission to an inpatient facility and/or evaluation and treatment in a healthcare facility for ≥24 hours) due to asthma.', ""Patient-reported productivity impairment assessment including work productivity, activity impairment, and disability will be collected via the WPAI-Asthma. Information will only be collected from procedures that are part of the patient's routine clinical care. WPAI Asthma questionnaire is calculated from 0 to 10 score (0 indicates-Asthma had no effect on my work/ daily activities and 10 indicates Asthma completely prevented me from working score/ doing my daily activities)."", 'Patient-reported assessment of asthma quality of life will be collected via the SGRQ. SGRQ, a disease specific health-related quality of life measure developed for both asthma and chronic obstructive pulmonary disease (COPD) patients. The SGRQ has 50 items and scores are calculated for 3 domains (symptoms, activity, and impact [psychosocial]) as well as total score.\n\nSymptoms - this component is concerned with the effect of respiratory symptoms, their frequency and severity.\n\nImpacts (psychosocial) - covers a range of aspects concerned with social functioning and psychological disturbances resulting from respiratory disease Activity - concerned with activities that cause or are limited by breathlessness. Total score summaries the impact of the disease on overall health status.\n\nThe score is expressed as a percentage of overall impairment, where 100 represents worst possible health status and 0 indicates best possible health status.', 'Patient evaluation of asthma treatment effectiveness will be measured using GETE; a simple measure of perceived treatment effectiveness. The patient will grade the overall treatment effectiveness using the following criteria: excellent (complete control of asthma); good (marked improvement of asthma); moderate (discernible, but limited improvement in asthma); poor (no appreciable change in asthma); or worsening (of asthma).', ""Frequency of relevant medical events such as weight gain (change in BMI), hypertension, dyslipidemia, pneumonia, bone densitometry results, osteoporosis / osteopenia, hip and spinal fractures, avascular necrosis, cataract, glaucoma, diabetes mellitus, cardiovascular disease, Cushing's syndrome, adrenal insufficiency, peptic ulcer disease, myopathy, pseudotumor cerebri, mood disturbance, and insomnia or sleep disturbance."", 'Frequency of relevant respiratory medical events such as pneumonia, pleural effusion, chronic bronchitis, allergic rhinitis.', 'Prevalence of respiratory comorbidities such as chronic obstructive pulmonary disease (COPD), bronchiectasis, alpha-1 anti-trypsin deficiency, Churg- Strauss syndrome (eosinophilic granulomatosis with polyangiitis [EGPA]), airway stenosis, cystic fibrosis, allergic bronchopulmonary aspergillosis,chronic eosinophilic pneumonia, bronchiolitis obliterans, immunodeficiency, primary ciliary dyskinesia, atelectasis, arterial hypertension, pulmonary hypertension, neuromuscular disease, allergic rhinitis, chronic rhinosinusitis, and pulmonary embolism.', 'Prevalence of non-respiratory comorbidities such as diabetes, thyroid disease, cardiac disease, etc.', 'Frequency of special interest events including new onset malignancy, severe infection, anaphylaxis, or mortality.', 'To assess complete blood count with differential including blood eosinophil count as a variable for asthma evaluation.', 'To assess total IgE as a variable for asthma evaluation.', 'Radiographic changes in asthma evaluation included chest X-rays (dates, views, description of major chest findings), Chest computed tomography scan (dates, high resolution (yes/no), intravenous contrast (yes/no), description of major findings). Radiographic asthma evaluation conducted as part of routine care.', 'FEV1 (liters and % predicted) will be assessed as a variable for asthma evaluation.', 'FEV1 (liters and % predicted) will be assessed as a variable for asthma evaluation.', 'To assess FENO as a variable for asthma evaluation.']"
0,64,['NCT04229212'],[],[],"['preoperation', 'postoperative days 1', 'postoperative days 2', 'postoperative days 4', 'postoperative days 10', 'Pre-operation', 'postoperative days 1', 'postoperative days 2', 'postoperative days 4', 'postoperative days 10']",[],[],[],[],['Completed'],['No'],[],['Not Applicable'],[],[],[],[],[],"['December 31, 2019']",['Actual'],"['mL', 'mL', 'mL', 'mL', 'mL', ""Mercuriali's formula: TBL = blood volume (BV) × (Hct [preop] - Hct [POD 4] + transfused RBC [mL])"", ""Mercuriali's formula: TBL = blood volume (BV) × (Hct [preop] - Hct [POD 4] + transfused RBC [mL])"", ""Mercuriali's formula: TBL = blood volume (BV) × (Hct [preop] - Hct [POD 4] + transfused RBC [mL])"", ""Mercuriali's formula: TBL = blood volume (BV) × (Hct [preop] - Hct [POD 4] + transfused RBC [mL])"", ""Mercuriali's formula: TBL = blood volume (BV) × (Hct [preop] - Hct [POD 4] + transfused RBC [mL])""]"
0,65,['NCT02848781'],[],[],['2 years'],[],['University of Chicago'],"['Roderick Tung, MD']",['Study Director'],['Recruiting'],['No'],[],['Not Applicable'],[],[],[],[],[],['February 2021'],['Anticipated'],['The primary endpoint is a composite.']
0,66,['NCT00385047'],[],[],['Up to 1 year'],[],['Walter Reed Army Institute of Research (WRAIR)'],"['Michele D. Spring, MD, M.S.P.H.']",['Principal Investigator'],['Completed'],['No'],[],"['Phase 1', 'Phase 2']",[],[],[],[],[],['April 2007'],['Actual'],[]
0,67,['NCT02993120'],[],[],"['Through study completion, an average of 3 years']",[],['Amgen'],['MD'],['Study Director'],"['Active, not recruiting']",['No'],['No'],[],[],[],[],[],[],"['July 6, 2021']",['Anticipated'],['Describe low-density lipoprotein (LDL) treatment patterns over time in subjects with clinical ASCVD']
0,68,['NCT03045120'],[],[],"['up to 24 months', 'up to 24 months']",[],['Bristol-Myers Squibb'],['Bristol-Myers Squibb'],['Study Director'],['Recruiting'],['No'],['No'],[],[],[],[],[],[],"['January 31, 2021']",['Anticipated'],[]
0,69,['NCT01154296'],[],"['1.1312', '1.1553', '0.9791', '1.0381', '0.07454', '0.08386', '0.03749', '0.03845']",['6 months post randomization'],"['250', '226', '28.6', '29.1', '17.4', '18.3', '2.7', '3.0', '1.1', '1.1', '115', '106']","['University of Miami', 'San Francisco Department of Public Health']","['Lisa R. Metsch, Ph.D.', 'Grant N Colfax, M.D.']","['Principal Investigator', 'Principal Investigator']",['Completed'],['Yes'],[],['Not Applicable'],['lm2892@columbia.edu'],['Department of Sociomedical Sciences/Mailman School of Public Health/Columbia University'],['212-305-3577'],[],"['Lisa Metsch, PhD, Stephen Smith Professor and Chair of Sociomedical Sciences']",['July 2011'],['Actual'],['Composite STI incidence (Yes/No) at 6-month follow-up in which a person is considered positive for STIs if they are positive on any tested STI.']
0,70,['NCT02857764'],[],[],"['up to 6 years (estimated study duration)', 'up to 6 years (estimated study duration)', 'up to 6 years (estimated study duration)']",[],"['Janssen Research & Development, LLC']","['Janssen Research & Development, LLC Clinical Trial']",['Study Director'],['Completed'],['No'],['No'],[],[],[],[],[],[],"['June 30, 2017']",['Actual'],"['The occurrence of a below-knee lower extremity amputation will be defined by observing an associated procedure code in the outpatient or inpatient medical service claims.', 'The occurrence of a below-knee lower extremity amputation will be defined by observing an associated procedure code in the outpatient or inpatient medical service claims.', 'Hazard ratio will be estimated using a conditional Cox proportional hazards model based on propensity-matched cohorts.']"
0,71,['NCT00412568'],[],[],['one year after procedure'],[],['Walter Reed Army Medical Center'],"['KRAIG S. BOWER, MD']",['Principal Investigator'],['Completed'],[],[],['Not Applicable'],[],[],[],[],[],[],[],[]
0,72,['NCT03353480'],[],[],"['0-72 hours', '0-72 hours']",[],['Pfizer'],['Pfizer CT.gov Call Center'],['Study Director'],['Completed'],['No'],[],['Phase 1'],[],[],[],[],[],"['January 29, 2018']",['Actual'],"['Area under the serum concentration-time profile from time zero to 72 hours post dose based on observed serum concentrations at time points 0 (prior-dose), 0.5, 1, 2, 3, 4, 5, 6,8, 10, 12, 24, 48 and 72 hours after dose using linear/log trapezoidal methods', 'Maximum serum concentration among observed serum concentrations at time points 0 (prior-dose), 0.5, 1, 2, 3, 4, 5, 6,8, 10, 12, 24, 48 and 72 hours after dose']"
0,73,['NCT00800267'],[],[],"['6 months', '6 months']",[],['Pfizer'],['Pfizer CT.gov Call Center'],['Study Director'],['Completed'],['No'],[],['Phase 3'],[],[],[],[],[],['June 1999'],['Actual'],[]
0,74,['NCT00601835'],"['6.01', '6.54', '0.371', '0.332']",[],['28 Days post-vaccination'],"['96', '97', '71', '71', '82', '84', '66', '63', '6.83', '7.35', '0.459', '0.409', '832', '209', '7', '5', '299', '132', '28', '20', '205', '93', '32', '11', '80', '32', '5', '2', '152', '53', '6', '1', '95', '40', '2', '1', '380', '122', '16', '4', '226', '90', '13', '6', '267', '61', '6', '2', '106', '34', '6', '1', '201', '74', '7', '1', '33', '6', '6', '1']",['Sanofi Pasteur Inc.'],['Medical Director'],['Study Director'],['Completed'],['No'],[],['Phase 4'],['RegistryContactUs@sanofipasteur.com'],['Sanofi Pasteur Inc.'],[],[],['Medical Director'],['July 2005'],['Actual'],['Seroprotection and booster responses for both tetanus and diphtheria were considered to be an antibody level of ≥ 0.10 IU/mL 28 days post-vaccination with either the Canadian-manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine or the US-manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine in participants ≥ 60 years of age.']
0,75,['NCT01087905'],[],[],"['26 weeks after the target quit smoking date', '26 weeks after the target quit smoking date']","['43.3', '48.9', '42.3', '49.9', '47.6', '44.6', '38.4', '48.2', '46.2', '51.6', '94', '118', '115', '128']","['University of Wisconsin Center for Tobacco Research and Intervention, School of Medicine and Public Health', 'University of Wisconsin Center for Tobacco Research and Intervention, School of Medicine and Public Health']","['Stevens S Smith, PhD', 'Paula A Keller, MPH']","['Principal Investigator', 'Study Director']",['Completed'],['No'],[],['Phase 4'],['sss@ctri.medicine.wisc.edu'],['University of Wisconsin School of Medicine and Public Health'],['608-262-7563'],[],"['Stevens S. Smith, Ph.D.']",['February 2011'],['Actual'],"['Self-reported total abstinence from any tobacco use (even a single puff) for the seven days preceding the target follow-up day.', 'Self-reported total abstinence from any tobacco use (even a single puff) for the seven days preceding the target follow-up day.']"
0,76,['NCT02616198'],[],[],"['6 years', '6 years', '6 years', '6 years', '6 years']",[],[],[],[],['Completed'],['Yes'],[],['Not Applicable'],[],[],[],[],[],['September 2009'],['Actual'],"['Marginal adaptation was evaluated by 2 independent clinicians. Visual inspection with a mirror at 18 inches was performed . A score means the higher score of clinical acceptability while C and D score means that the restoration has failed and needs to be replaced. Alpha 1: Harmonious outline Alpha 2: Marginal gap (max 100µ) with discoloration (removable) Bravo: Marginal gap (> 100µ) with discoloration (unremovable) Charlie: The restoration is fractured or missed', 'Marginal discolouration was evaluated by 2 independent clinicians. Visual inspection with a mirror at 18 inches was performed . A score means the higher score of clinical acceptability while C score means that the restoration has failed and needs to be replaced. Alpha: No discoloration anywhere along the margin between the restoration and the adjacent tooth.\n\nBravo: Slight discoloration along the margin between the restoration and the adjacent tooth.\n\nCharlie: The discoloration penetrated along the margin of the restorative material in a pulpal direction.', 'Retention rate was evaluated by 2 independent clinicians. Visual inspection with a mirror at 18 inches was performed . A score means the higher score of clinical acceptability while C and D score means that the restoration has failed and needs to be replaced. Alpha 1:Clinically excellent Alpha 2: Clinically good with slight deviations from ideal performance, correction possible without damage of tooth or restoration Bravo: Clinically sufficient with few defects, corrections or repair of the restoration possible Charlie: Restoration is partially missed Delta: Restoration is totally missed', 'Anatomic form was evaluated by 2 independent clinicians. Visual inspection with a mirror at 18 inches was performed . A score means the higher score of clinical acceptability while C score means that the restoration has failed and needs to be replaced. Alpha 1: Continuous with existing anatomical form Alpha 2: Slightly discontinuous due to some chipping on the proximal ridge Bravo: Discontinuous with existing anatomical form due to material loss but proximal contact still present Charlie: Proximal contact is lost with ridge fracture', 'Colour changes was evaluated by 2 independent clinicians. Visual inspection with a mirror at 18 inches was performed . A score means the higher score of clinical acceptability while C score means that the restoration has failed and needs to be replaced. Alpha: The restoration matches the adjacent tooth structure in color and translucency.\n\nBravo: Light mismatch in color, shade or translucency between the restoration and the adjacent tooth.\n\nCharlie: The mismatch in color and translucency is outside the acceptable range of tooth color and translucency.']"
0,77,['NCT00007540'],[],[],[],[],[],[],[],['Completed'],[],[],[],[],[],[],[],[],[],[],[]
0,78,['NCT02163525'],[],[],"['3 months post procedure', '30 days post procedure']",[],['Henry Ford Hospital'],"['David Eisenstein, MD']",['Study Director'],"['Active, not recruiting']",['Yes'],[],['Not Applicable'],[],[],[],[],[],['July 2019'],['Actual'],"['To compare medical, surgical, and hospitalization costs (including procedural complication costs) of Global Fibroid Ablation (GFA) compared to those of Myomectomy and Uterine Artery Embolization (UAE)at 3 months post procedure.', 'Overall rates of acute (within 48 hours post procedure) and near-term (between 2 and 30 days post procedure) serious complications in all GFA subjects compared to the acute and near-term treatment-related serious adverse event rates in the pivotal study.']"
0,79,['NCT03310112'],[],[],"['Change from the pre-intervention baseline (testing 1) to the long-term post-intervention (testing 3), which is an average of 8 weeks from the baseline.', 'Change from the pre-intervention baseline (testing 1) to the long-term post-intervention (testing 3), which is an average of 8 weeks from the baseline.']",[],['University of Miami'],"['Amishi P Jha, Ph.D.']",['Principal Investigator'],['Completed'],['No'],[],['Not Applicable'],[],[],[],[],[],"['March 27, 2018']",['Actual'],"['The SART is used to assess attentional performance and mind wandering (i.e., off-task thinking which is typically self-generated and compromises the performance of the task at hand). The task uses a continuous performance paradigm involving button presses to frequently presented non-targets (numbers 1, 2, 4, 5, 6, 7, 8, and 9) but requires the participants to withhold their motor response to the infrequent target (number 3). Withholding responses only to infrequent targets encourages a pre-potent response and mind wandering. Real-time subjective experience of mind wandering during SART is assessed through experience-sampling probes randomly presented throughout the task.', 'The WMDA is used to assess the ability to hold information in working memory while overcoming emotional reactivity and distraction. Specifically, participants are presented with a memory item that they need to memorize and hold in memory during a delay interval. During the delay, emotionally negative or neutral scene images are presented. The negative images are combat scenes from Iraq or Afghanistan and the neutral images are non-combat scenes.']"
0,80,['NCT02766634'],[],[],"['prior to study drug administration on Days 1, 2, 3, 4, 5, and 24, 48, 72, 96, and 120 hours after dose administration on Day 5 of each period', 'prior to study drug administration on Days 1, 2, 3, 4, 5, and 24, 48, 72, 96, and 120 hours after dose administration on Day 5 of each period', 'prior to study drug administration and 24, 48, 72, 96, and 120 hours after dose administration on Day 5 of each period', 'prior to study drug administration and 24, 48, 72, 96, and 120 hours after dose administration on Day 5 of each period']",[],['Pfizer'],['Pfizer CT.gov Call Center'],['Study Director'],['Completed'],['No'],[],['Phase 1'],[],[],[],[],[],['June 2016'],['Actual'],[]
0,81,['NCT02971709'],[],[],['One-year'],[],"['Klein Buendel, Inc.']","['David Buller, PhD']",['Principal Investigator'],['Completed'],['No'],[],['Not Applicable'],[],[],[],[],[],"['May 31, 2017']",['Actual'],"['Any use of each passive recreation, assessed by observing each passive recreation areas for 30 minutes on four weekend days between 11 am and 3 pm when forecast high temperatures were had forecast high temperature were between 72°F/22°C and 95°F/35°C over a 20-week period during two summers (pretest summer, posttest summer) by trained research assistants. Observations were suspended during rain.']"
0,82,['NCT03801928'],[],[],"['From Baseline through 12 months', 'From Baseline thtough 12 months', 'From Baseline through 12 months', 'From Baseline through 12 months', 'From Baseline through 12 months']",[],['Pfizer'],['Pfizer CT.gov Call Center'],['Study Director'],['Completed'],['No'],['No'],[],[],[],[],[],[],"['February 7, 2020']",['Actual'],[]
0,83,['NCT01641029'],[],[],['July 2013-July 2014'],[],[],[],[],['Completed'],['No'],['No'],[],[],[],[],[],[],['December 2014'],['Actual'],[]
0,84,['NCT02128542'],"['62.0', '60.4', '64.3', '66.9']",[],"['Posttreatment Week 12', 'Up to 12 weeks']","['76.6', '84.2', '4.5', '78.7', '89.5', '0', '0', '17.4', '15.8', '2', '5', '0', '0']",['Gilead Sciences'],"['Lorenzo Rossaro, MD']",['Study Director'],['Completed'],['No'],[],['Phase 4'],['ClinicalTrialDisclosures@gilead.com'],['Gilead Sciences'],[],[],['Clinical Trial Disclosures'],['June 2015'],['Actual'],"['SVR12 was defined as HCV RNA < the lower limit of quantitation (LLOQ; ie, 25 IU/mL) at 12 weeks after stopping study treatment.']"
0,85,['NCT00573976'],[],[],[],[],"['University of California, Irvine']","['Kimberly D Anderson, Ph.D.']",['Principal Investigator'],['Completed'],['No'],[],[],[],[],[],[],[],[],[],[]
0,86,['NCT00306007'],[],[],[],[],"['University of California, San Francisco', 'University of California, San Francisco']","['Jody Steinauer, MD, MAS', 'Diane Morof, MD, MSc']","['Principal Investigator', 'Study Director']",['Completed'],['No'],['No'],[],[],[],[],[],[],['August 2007'],['Actual'],[]
0,87,['NCT02766647'],[],[],"['1 hour prior to dose administration and 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, and 48 hours after dose administration', '1 hour prior to dose administration and 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, and 48 hours after dose administration', '1 hour prior to dose administration and 0.5, 1, 2, 4, 6, 8, 24, 48, 72, 96 and 120 hours after dose administration', '1 hour prior to dose administration and 0.5, 1, 2, 4, 6, 8, 24, 48, 72, 96 and 120 hours after dose administration']",[],['Pfizer'],['Pfizer CT.Gov Call Center'],['Study Director'],['Completed'],['No'],[],['Phase 1'],[],[],[],[],[],['February 2016'],['Actual'],[]
0,88,['NCT04460898'],[],[],"['mBC diagnosis through end of study (assessed up to 24 months)', 'mBC diagnosis through end of study (assessed up to 24 months)', 'mBC diagnosis through end of study (assessed up to 24 months)', 'mBC diagnosis through end of study (assessed up to 24 months)', 'mBC diagnosis through end of study (assessed up to 24 months)', 'mBC diagnosis through end of study (assessed up to 24 months)', 'mBC diagnosis through end of study (assessed up to 24 months)']",[],['Pfizer'],['Pfizer CT.gov Call Center'],['Study Director'],['Completed'],[],['No'],[],[],[],[],[],[],"['June 24, 2019']",['Actual'],[]
0,89,['NCT00413517'],[],[],['12 months after procedure'],[],['Walter Reed Army Medical Center'],"['KRAIG S. BOWER, MD']",['Principal Investigator'],['Completed'],[],[],['Not Applicable'],[],[],[],[],[],[],[],[]
0,90,['NCT02882100'],[],[],"['up to 1 year', 'up to 1 year']",[],"['Case Western Reserve Univsity', 'Brown University', 'Insight Therapeutics, LLC']","['Stefan Gravenstein, MD, MPH', 'Vincent Mor, PhD', 'H. Edward Davidson, PharmD, MPH']","['Principal Investigator', 'Principal Investigator', 'Principal Investigator']","['Active, not recruiting']",['No'],[],['Phase 4'],[],[],[],[],[],"['October 4, 2018']",['Actual'],"['Time to first occurrence of hospitalization for a respiratory-related Illness based upon Medicare inpatient hospital claims', 'Time to first occurrence of hospitalization for all-causes']"
0,91,['NCT00533975'],[],[],[],[],"['UCSD, VA San Diego']","['Samuel B Ho, M.D.']",['Principal Investigator'],['Unknown status'],['No'],[],[],[],[],[],[],[],[],[],[]
0,92,['NCT02109757'],[],[],['6 mos after intial subject visit'],[],['United States Air Force School of Aerospace Medicine'],"['Quintin A Hecht, Au.D.']",['Principal Investigator'],['Unknown status'],['Yes'],[],['Not Applicable'],[],[],[],[],[],['October 2015'],['Anticipated'],"['The experimental group will show an increase, larger than the control group, in the amount of personal attenuation rating measurement shown by the software program as a result of software intervention used before and after education at the initial and follow-up visits.']"
0,93,['NCT00959933'],[],[],['30 days'],[],['Allied Clinical Research'],"['Piyush Patel, M.D.']",['Principal Investigator'],['Completed'],[],[],['Phase 1'],[],[],[],[],[],['May 2001'],['Actual'],[]
0,94,['NCT00960479'],[],[],['30 days'],[],['Allied Clinical Research'],"['Piyush Patel, M.D.']",['Principal Investigator'],['Completed'],[],[],['Phase 1'],[],[],[],[],[],['February 2001'],['Actual'],[]
0,95,['NCT03266497'],[],[],['2003-2012'],[],[],[],[],['Completed'],['No'],['No'],[],[],[],[],[],[],['December 2012'],['Actual'],"['Components include: fruit (excluding fruit juice) (s/d); vegetables (excluding white potatoes) (s/d); whole grains (oz-equivalents/d); sugar-sweetened beverages (s/d); nuts, legumes, and vegetable protein (oz-equivalents/d); red/processed meat (s/d); long-chain omega-3 fats (EPA+DHA; mg/d); polyunsaturated fats (PUFA; % kcal/d); sodium (mg/d); and alcohol (drinks/d). Potential range of 0-100 points and higher scores indicative of higher diet quality']"
0,96,['NCT02207569'],"['1.1', '1.7', '62.3', '93.3', '0.0', '0.1', '10.6', '0.4', '4.4', '14.7', '4.8']","['10', '3.1', '3.8', '4.8', '0.2', '0.5', '0.5', '0.5']","['Assessed at 30 days post-implantation', 'Assessed at 30 days post-implantation', 'Assessed at 24 hours to seven days post implantation', 'Assessed at 24 hours to 7 days post implantation']","['2.5', '3.3', '69.2', '96.5', '0.0', '0.4', '14.5', '1.3', '7.1', '19.7', '96.9', '48.2', '7.8', '8.4', '9.0', '7.5', '0.6', '1.9', '1.8', '1.8', '5.7', '5.4', '3.7']",['New York Langone Medical Center'],"['Mathew R Williams, MD']",['Principal Investigator'],"['Active, not recruiting']",['Yes'],[],['Not Applicable'],['sara.m.saul@medtronic.com'],['Medtronic'],['763-526-1965'],[],['Sara Saul'],['August 2015'],['Actual'],"['Percentage of patients that died by any cause at 30 days', 'Stroke Diagnostic Criteria:\n\n>\n\nAcute episode of focal or global neurological deficit with at least 2 of the following:\n\nchange in level of consciousness >\nhemiplegia, hemiparesis\nnumbness or sensory loss affecting 1 side >\ndysphasia or aphasia\nhemianopia\namaurosis fugax >\n\nother neurological signs or symptoms consistent with stroke\n\n2.) No other readily identifiable non-stroke cause or the clinical presentation, to be determined by or in conjunctions with the designated neurologist\n\n3.) Confirmation of the diagnosis by at least 1 of the following:\n\nNeurological specialist >\nNeuroimaging procedure, or on clincial grounds alone > Stroke: durations of neural deficit > 24 h if available neuroimaging documents a new hemofrrhage or infarct; or the neurological deficit results in death\n\nDefined by VARC II:\n\n> An mRS (Modified Rankin Score) of 2 or more at 90 days and an increase in at least 1 mRS category from pre-stroke baseline', 'Percentage of patients with Device Success defined as:\n\nAbsence of procedural mortality, AND\nCorrect positioning of a single Evolut R valve into the proper anatomical location, AND\nAbsence of patient-prosthesis mismatch, and mean gradient , 20 mm Hg (or peak velocity < 3m/sec, AND\nAbsence of moderate or severe prosthetic valve regurgitation', 'Percentage of patience with none, trace or mild total prosthetic regurgitation at early post procedure echo cardiogram (24 hours to 7 days) as evaluated by echo core lab.']"
0,97,['NCT02569632'],[],[],['18 months'],[],"[""Children's Hospital Oakland Research Institute, Center for Immunobiology and Vaccine Development""]","['Dan Granoff, MD']",['Principal Investigator'],['Unknown status'],['No'],[],['Phase 4'],[],[],[],[],[],['May 2017'],['Anticipated'],['Determine the percentage of subjects achieving serum bactericidal titers of 1:4 or greater in serum obtained 1 month after doses 2 and 3 as measured against a panel of 15 genetically diverse meningococcal strains.']
0,98,['NCT02069925'],[],[],"['3 months', '3 years']",[],['Yale University'],"['Vinod Srihari, MD']",['Principal Investigator'],"['Active, not recruiting']",['Yes'],[],['Not Applicable'],[],[],[],[],[],"['February 27, 2020']",['Actual'],"['The primary outcome of interest, proportion of participants at each site with DUP < 3 months, will be calculated for the ""pre period"" (first year of the study, prior to initiation of ED intervention at STEP)']"
0,99,['NCT03433131'],[],[],[],[],['Albert Einstein College of Medicine'],"['Michael Thorpy, MD']",['Principal Investigator'],['No longer available'],[],[],[],[],[],[],[],[],[],[],[]
0,100,['NCT02746809'],"['0.2', '0.0', '65.9', '93.9', '1.6', '0.2', '0.2', '0.0', '0.0', '0.0', '12.1']","['10.3', '3.2', '3.5', '0.2', '0.7', '0.7']","['30 Days', '30 Days', '24 hours to 7 days post implantation', '24 hours to 7 days post implantation']","['1.7', '0.0', '79.2', '100.0', '5.0', '1.7', '1.7', '0.0', '0.0', '0.0', '20.8', '100.0', '41.5', '6.4', '6.7', '0.8', '2.6', '2.3', '60.3', '72.0']",['NYU Langone Medical Center'],"['Mathew R Williams, MD']",['Principal Investigator'],"['Active, not recruiting']",['Yes'],[],['Not Applicable'],['sara.m.saul@medtronic.com'],['Medtronic'],['763-526-1965'],[],['Sara Saul'],['November 2016'],['Actual'],"['Percentage of participants with all-cause mortality at 30 days', 'Percentage of participants with disabling stroke (VARC-II definitions) at 30 days', 'Device Success defined as:\n\nAbsence of procedural mortality, AND\nCorrect positioning of a single prosthetic heart valve into the proper anatomical location, AND\nIntended performance of the prosthetic heart valve, defined as the absence of patient prosthesis-mismatch and mean gradient < 20 mmHg (or peak velocity < 3 m/sec), AND\nAbsence of moderate or severe prosthetic valve regurgitation', 'The percentage of subjects with no more than mild prosthetic regurgitation at early post procedure echocardiogram as assessed by echo core laboratory']"
0,101,['NCT00328380'],[],[],[],[],[],[],[],['Completed'],[],[],['Phase 3'],[],[],[],[],[],['December 2006'],['Actual'],[]
0,102,['NCT04552535'],[],[],['Up to 3 months'],[],[],[],[],['Completed'],[],['No'],[],[],[],[],[],[],"['May 18, 2020']",['Actual'],['Time on treatment with afatinib or chemotherapy during 2L. Time on treatment is defined as the interval from the start of 2L treatment until the end of 2L treatment or death date by any cause.']
0,103,['NCT03293875'],[],[],"['Every 30 days up to 192 weeks', 'six and twelve months after the roll out of the intervention components', 'six and twelve months after the roll-out of the intervention components']",[],"['Lehigh University', '9155842875']","['Julia Lechuga, PhD', 'Rebeca Ramos, MPH']","['Principal Investigator', 'Study Director']",['Recruiting'],['Yes'],[],['Not Applicable'],[],[],[],[],[],['December 2020'],['Anticipated'],"['rates of number of individuals who get tested on a 30- day period for HIV using a coupon', 'number of sexual partners (primary and casual), number of instances of unprotected anal, vaginal, oral sex, engagement in sexual relations while using drugs', 'frequency of injection drug use, frequency of needle sharing']"
0,104,['NCT01235260'],[],[],"['From time of recruitment beginning in October 1, 1999 until the earliest of September 30, 2007, outcome identification, or death.', 'From time of accrual beginning in October 1, 1999 until the earliest of September 30, 2007 or death.']",[],"['Johnson & Johnson Pharmaceutical Research & Development, L.L.C.']","['Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial']",['Study Director'],['Completed'],[],[],[],[],[],[],[],[],['March 2011'],['Actual'],[]
0,105,['NCT03390660'],[],[],"['till age 5', 'till age 6 months']",[],[],[],[],['Completed'],['No'],['No'],[],[],[],[],[],[],"['December 31, 2014']",['Actual'],"['whether the child has ever been breastfed', 'whether the child was breastfed at age 6 months']"
0,106,['NCT00837499'],[],[],['5 years'],[],['M.D. Anderson Cancer Center'],"['Abenaa M. Brewster, MD, MHS, BS']",['Principal Investigator'],"['Active, not recruiting']",['No'],[],[],[],[],[],[],[],"['September 30, 2020']",['Anticipated'],[]
0,107,['NCT01629537'],[],[],['1 week'],[],"['United States Naval Medical Center, San Diego']","['Steven Hanling, MD, CDR']",['Principal Investigator'],['Completed'],['Yes'],[],['Phase 2'],[],[],[],[],[],['April 2016'],['Actual'],"['The CAPS is generally considered the gold standard for PTSD assessment, and will be used to determine severity of PTSD symptoms compared to the 1 week pre baseline measures at enrollment']"
0,108,['NCT00351741'],[],"['9', '9', '11', '10']",['28 days'],"['12', '11', '15', '15', '6', '6', '10', '16', '2', '9', '0', '4', '2', '0']",['United States Army Insitute of Surgical Research'],"['Kevin K Chung, MD']",['Principal Investigator'],['Terminated'],['No'],[],['Not Applicable'],['kevin.chung@us.army.mil'],['USAISR'],['210-916-3054'],[],['Principal Investigator'],['February 2010'],['Actual'],"['The primary end point was ventilator-free days in the first 28 days, defined as the number of days after randomization from day 0 to day 28 alive without ventilator assistance for at least 48 consecutive hrs.']"
0,109,['NCT01965561'],[],"['23', '14', '40', '31']",['1 min'],"['97', '27', '83', '93', '30', '76', '45', '43']",['United States Army Institute of Surgical Research'],"['John F Kragh, MD']",['Principal Investigator'],['Completed'],['No'],[],['Phase 4'],['john.f.kragh.civ@mail.mil'],['USAISR'],['210.539.2210'],[],"['John Kragh, MD']",['December 2013'],['Actual'],['Percentage of participants whose distal pulse ceased within 1 minute of junctional tourniquet application.']
0,110,['NCT01927835'],[],[],"['Measured within the initial 7-day period following each vaccination visit and followed until resolution', ""Measured through participants' last study visit at Month 12"", ""Measured through the end of participants' 3-year follow-up period"", ""Measured through participants' last study visit at Month 12"", 'Measured 2 weeks after the second NYVAC+AIDSVAX B/E boost or final placebo injection', 'Measured 2 weeks after the second NYVAC+AIDSVAX B/E boost or final placebo injection', 'Measured 2 weeks after the second NYVAC+AIDSVAX B/E boost or final placebo injection', ""Measured through participants' last study visit at Month 12"", ""Measured through participants' last study visit at Month 12"", ""Measured through participants' last study visit at Month 12"", ""Measured through participants' last study visit at Month 12""]",[],['Columbia University'],['Magdalena Sobieszczyk'],['Study Chair'],['Withdrawn'],['Yes'],[],['Phase 1'],[],[],[],[],[],['January 2017'],['Anticipated'],"['Including pain, tenderness, maximum severity of pain and/or tenderness, erythema, induration, fever, malaise/fatigue, myalgia, headache, nausea, vomiting, chills, arthralgia, and maximum severity of systemic symptoms', 'Including by treatment arm, by body system, Medical Dictionary for Regulatory Activities (MedDRA) preferred term, severity, and assessed relationship to study products', 'Including boxplots of white blood cells (WBC), neutrophils, lymphocytes, hemoglobin, platelets, alanine aminotransferase (ALT), and creatinine at baseline and following vaccinations, by treatment arm']"
0,111,['NCT01704235'],[],[],['Duration of the study; Up to 1 year'],[],['Oregon Health and Science University'],"['Lillian Nail, PhD']",['Principal Investigator'],['Completed'],['No'],[],[],[],[],[],[],[],"['November 30, 2013']",['Actual'],"[""To understand the extent of symptom perception among Vietnamese American women (foreign and United States-born) and their impact on cervical cancer screening from the perspective and experiences of key informants including primary health care providers. A semi-structured interview guide will be used to assess the extent of preventive care-seeking. The interview guide includes the following topics: thoughts and experiences regarding Vietnamese American women's knowledge and beliefs about how cervical cancer develops, thoughts and experiences regarding Vietnamese American women and use of cancer screening tests such as cervical cancer screening for early detection/preventive health care, thoughts and experiences about Vietnamese American women's lack of familiarity with the term Pap smear or a Pap test, and thoughts and experiences regarding Vietnamese American women's decision and timing to seek medical care and preventive health care.""]"
0,112,['NCT01306266'],[],[],['2 hours'],[],['U.S. Army Medical Corp. Madigan Army Medical Center'],"['Jay C Erickson, MD']",['Principal Investigator'],['Withdrawn'],['No'],[],['Not Applicable'],[],[],[],[],[],['August 2011'],['Actual'],['proportion of subjects who obtain headache relief defined as no pain or mild pain two hours after dosing']
0,113,['NCT00796315'],[],"['51.2', '27.9', '45.4', '22.5', '19.9', '42.9']","['72 Hours', '72 Hours']","['461.9', '810.1', '827.0', '50.1', '65.8', '63.2']",['Procter and Gamble'],"['Molly Seeck, BS, JD']",['Study Director'],['Completed'],['No'],[],['Phase 1'],['balan.g@pg.com'],['Procter & Gamble'],['513.622.2657'],[],['Guhan Balan'],['June 2009'],['Actual'],"['Area under the time-concentration curve for Doxylamine from 0 to 72 hours post-dose plus an extrapolated area from 72 hours to infinity.', 'Maximum concentration of Doxylamine from 0 to 72 hours post-dose']"
0,114,['NCT00005463'],[],[],[],[],[],[],[],['Completed'],[],[],[],[],[],[],[],[],[],[],[]
0,115,['NCT03382418'],[],[],"['Measured through Week 2', 'Measured through Week 2', 'Measured through Week 2', 'Measured through Week 2']",[],"['University of Pennsylvania', 'New York Blood Center']","['Katharine Bar', 'Hong Van Tieu']","['Study Chair', 'Study Chair']",['Completed'],['Yes'],[],['Phase 1'],[],[],[],[],[],"['September 25, 2019']",['Actual'],"['Signs/symptoms may include pain, tenderness, maximum severity of pain and/or tenderness, erythema, induration, fever, malaise/fatigue, myalgia, headache, nausea, vomiting, chills, arthralgia, maximum severity of systemic symptoms (graded using the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. Corrected Version 2.1, dated July 2017)', 'Signs/symptoms may include pain, tenderness, maximum severity of pain and/or tenderness, erythema, induration, fever, malaise/fatigue, myalgia, headache, nausea, vomiting, chills, arthralgia, maximum severity of systemic symptoms (graded using the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. Corrected Version 2.1, dated July 2017)', 'Categorized by Medical Dictionary for Regulatory Activities (MedDRA) preferred term, severity, and assessed relationship to study products (graded using the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. Corrected Version 2.1, dated July 2017)', 'Categorized by MedDRA preferred term, severity, and assessed relationship to study products (graded using the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. Corrected Version 2.1, dated July 2017)']"
0,116,['NCT00054743'],[],[],[],[],[],[],[],['Completed'],[],[],['Phase 4'],[],[],[],[],[],[],[],[]
0,117,['NCT00730964'],[],[],['Within 24 hours post contrast administration'],"['0', '6']",['GE Healthcare'],"['Rubin Sheng, MD']",['Study Director'],['Completed'],['Yes'],[],['Phase 4'],['Rubin.Sheng@ge.com'],['GE Healthcare'],['1-609-514-6899'],[],"['Rubin Sheng, MD']",['October 2009'],['Actual'],"['A Serious Adverse Reaction or (SAR) is considered causally related to the Optison product administered by the investigator. This reaction, should it occur, will be counted as a serious adverse reaction.']"
0,118,['NCT02886689'],[],[],['first year'],[],"['Central Hospital, Nancy, France', 'CHU, Rouen, France', 'CHU de la Cavale Blanche, Brest, France', 'Hopital Cochin, Paris, France', 'CHU Hautepierre, Strasbourg, France', 'Hopital Necker, Paris , France', 'CHU Minioz, Besançon, France']","['Francis Guillemin, MD, PhD', 'Jacques Benichou, MD, PhD', 'Alain Sasraux, MD, PhD', 'Loic Guillevin, MD, PhD', 'Jean Sibilia, MD, PhD', 'Anne Marie Prieur, MD, PhD', 'Daniel Wendling, MD, PhD']","['Study Chair', 'Principal Investigator', 'Principal Investigator', 'Principal Investigator', 'Principal Investigator', 'Principal Investigator', 'Principal Investigator']",['Completed'],['Yes'],[],[],[],[],[],[],[],['December 2010'],['Actual'],[]
0,119,['NCT00005455'],[],[],[],[],[],[],[],['Completed'],[],[],[],[],[],[],[],[],[],[],[]
0,120,['NCT01150695'],[],[],"['Throughout the course of the study.', 'Visits 7 or 8 post vaccination (Day 28 or Day 56).', 'Through Day 28 of the study.', 'By study Visit 5 (7-9 days post vaccination).']",[],[],[],[],['Completed'],[],[],['Phase 2'],[],[],[],[],[],['January 2012'],['Actual'],[]
0,121,['NCT00245076'],[],[],[],[],['National Cancer Institute (NCI)'],"['Jacqueline Stoddard, PhD, MA']",['Principal Investigator'],['Completed'],[],[],['Not Applicable'],[],[],[],[],[],[],[],[]
0,122,['NCT00935623'],[],[],['28 days post challenge'],[],"['US Military Malaria Vaccine Program, Naval Medical Research Center']","['Ilin Chuang, MD, MPH']",['Principal Investigator'],['Completed'],['No'],[],['Phase 1'],[],[],[],[],[],['June 2011'],['Actual'],[]
0,123,['NCT03688126'],[],[],['up to 2 years'],[],"['Wake Forest University Health Sciences', 'Wake Forest University Health Sciences', 'University of California, Davis', 'Karolinska Institutet']","['Laura D Baker, PhD', 'Mark A Espeland, PhD', 'Rachel A Whitmer, PhD', 'Miia Kivipelto, MD, PhD']","['Principal Investigator', 'Principal Investigator', 'Principal Investigator', 'Principal Investigator']",['Recruiting'],['No'],[],['Not Applicable'],[],[],[],[],[],['November 2023'],['Anticipated'],"['Global cognitive function will be obtained from a composite score derived from subtest scores on the POINTER modified Neuropsychological Test Battery (PmNTB) that includes: Free and Cued Selective Reminding Test, Story Recall, Visual Paired Associates, Number Span, Word Fluency, Trail-Making Test, and Digit Symbol Substitution Test. Scores from each individual test will be converted to z-scores that typically range from -3 to 3, with higher scores reflecting better performance, and averaged to form a composite. The primary outcome is the slope of these composite scores over repeated assessments (standard deviation units per year), with less negative (or positive) slopes reflecting better performance.']"
0,124,['NCT02053506'],[],[],['daily until skin barrier restored (~5-10 days)'],[],['United States Army Research Institute of Environmental Medicine'],"['Tracey J Smith, PhD']",['Principal Investigator'],['Completed'],['No'],[],['Not Applicable'],[],[],[],[],[],['May 2016'],['Actual'],"['Skin barrier restoration is assessed via transepidermal water loss (TEWL). Skin barrier is considered ""restored"" when TEWL returns to within 90% of baseline levels.']"
0,125,['NCT03933215'],[],[],['Baseline (Month 0) up to 24 Months'],[],"['EMD Serono Inc., the biopharmaceutical division of Merck KGaA, Darmstadt, Germany']",['Medical Responsible'],['Study Director'],['Recruiting'],['No'],['No'],[],[],[],[],[],[],"['November 29, 2023']",['Anticipated'],"['For this study, a relapse will be defined as per routine clinical practice as determined by the investigator. As a guide, relapse may be defined as exacerbation of symptoms that occur over a minimum of 24 hours and separated from a previous attack by at least 30 days, in the absence of fever or infection. ARR up to 24 months of treatment with cladribine tablets, after baseline (prospectively collected data) will be reported.']"
0,126,['NCT03933202'],[],[],['Baseline (Month 0) up to 24 Months'],[],"['EMD Serono Inc., the biopharmaceutical division of Merck KGaA, Darmstadt, Germany']",['Medical Responsible'],['Study Director'],['Recruiting'],['No'],['No'],[],[],[],[],[],[],"['May 3, 2023']",['Anticipated'],"['A relapse will be defined as per routine clinical practice as determined by the investigator. As a guide, relapse may be defined as exacerbation of symptoms that occur over a minimum of 24 hours and separated from a previous attack by at least 30 days, in the absence of fever or infection. ARR up to 24 months of treatment with cladribine tablets, after baseline (prospectively collected data) will be reported.']"
0,127,['NCT00005171'],[],[],[],[],[],[],[],['Completed'],[],[],[],[],[],[],[],[],[],[],[]
0,128,['NCT01256164'],[],"['1.3', '3.1']",['0-10 minutes'],"['1.9', '4.8', '47', '23', '39', '8', '44', '14', '47', '18']",['Mallinckrodt'],"['Paul Frohna, MD, PhD']",['Study Director'],['Completed'],['No'],[],['Not Applicable'],['lawrence.hill@mallinckrodt.com'],['Mallinckrodt'],['908-238-6370'],[],['Lawrence Hill'],['September 2011'],['Actual'],['Time to hemostasis recorded from the first application of study treatment until cessation of bleeding']
0,129,['NCT03631472'],[],[],['12 months'],[],[],[],[],"['Active, not recruiting']",['No'],[],['Not Applicable'],[],[],[],[],[],"['August 30, 2020']",['Anticipated'],['Incidence of serious adverse events associated with RheOX through 6 months.']
0,130,['NCT03699709'],[],[],"['measured at baseline, and months 6 and 12', 'measured at baseline, and months 6 and 12']",[],['University of Washington'],"['Amanda M Fretts, PhD']",['Principal Investigator'],"['Active, not recruiting']",['No'],[],['Not Applicable'],[],[],[],[],[],"['November 30, 2021']",['Anticipated'],"['Sugar-sweetened beverages include self-reported intake of fruit drinks, sugar-based energy drinks, and soda. Intake of sugar-sweetened beverages will be estimated using measures of consumption frequency and portion size. Average intakes will be calculated for each study participant using the University of Minnesota Nutrition Data Systems for Research Software by multiplying the frequency response for each beverage on the food frequency questionnaire by the recalled portion size, and then summing for all relevant beverages. Change from baseline with be assessed at 6 months and 12 months (12 months - baseline; 6 months - baseline). As the intervention hopes to decrease intake of sugar-sweetened beverages, lower (i.e., more negative) after - before differences represent a better outcome.', 'Change in healthy and unhealthy food purchases will be estimated using the Healthy/Unhealthy Food Acquisition Survey. The survey includes a list of 47 healthy and unhealthy foods commonly consumed in the community. At each exam (baseline, month 6, month 12), participants will report the number of times he/she acquired each of the 47 foods in the past 30 days. Change from baseline with be assessed at 6 months and 12 months (12 months - baseline; 6 months - baseline). As the intervention hopes to increase the number of healthy food purchases and decrease the number of unhealthy food purchases, higher after - before differences represent a better outcome for healthy foods and lower after - before differences represent a better outcome for unhealthy foods.']"
0,131,['NCT00237263'],[],[],[],[],['Novartis Pharmaceuticals'],['Novartis Pharmaceuticals'],['Study Chair'],['Completed'],[],[],['Phase 2'],[],[],[],[],[],['July 2007'],['Actual'],[]
0,132,['NCT02939131'],"['3.7', '8.8', '39', '7.0', '22.7', '7.2', '466', '524', '1.48', '1.47', '2.40', '0.0', '1.56', '0.05', '0.0', '0.0']",[],"['Week 24', 'Week 0 and Week 24', 'Week 24', 'Week 24', 'Week 24']","['6.7', '10.6', '62.3', '17.9', '47.9', '17.0', '703', '683', '2.23', '2.06', '9.27', '9.11', '10.48', '7.92', '5.59', '1.19']",['Rhode Island Hospital; Brown University'],"['Larry Brown, MD']",['Study Chair'],['Completed'],['Yes'],[],['Not Applicable'],['mallen@fhi360.org'],['Family Health International (FHI 360)'],['(919) 405-1429'],[],"['Melissa Allen, Director, IMPAACT Operations Center']","['September 12, 2019']",['Actual'],"['The QIDS-SR ranges from 0-27 and assesses the severity and number of depression symptoms. Data completed through the Audio Computer Assisted Interview (ACASI) system are used for this outcome. A lower score indicates fewer depression symptom severity. Scores for all participants at a site were averaged. The site-specific averages were then analyzed.', 'We are assessing the percentage of participants with a response to treatment.The percentage of participants at each site with a response was calculated. These percentages were averaged for each treatment and the treatment averages were compared. A response to treatment is considered a decrease in Quick Inventory of Depression Symptomatology, Self Report (QIDS-SR) from Study entry to Week 24 by more than 50%. The week 0 value is generally considered the entry value. Priority is given to the ACASI score at week 0. In certain cases, the week 1 ACASI value is used if there is no ACASI score at week 0, but there is one at week 1. Paper form scores are used for ""study entry"" if there is no ACASI record, with the value at week 0 prioritized over the value at week 1. Otherwise, ACASI data are used for this outcome. The QIDS-SR is scored from 0 to 27 with a lower score indicating less symptomatology.', 'We computed the percentage of participants at each site with remission and then compared the percentages. Remission is defined as a Quick Inventory of Depression Symptomatology, self-report (QIDS-SR) score <= 5. ACASI data are used for this outcome. The QIDS-SR scale is from 0-27 with a lower score indicating tess symptomatology.', 'CD4 cell counts are cells/microL (uL). CD4 cell counts of all participants at a site were averaged. The averages were then analyzed.', 'Plasma HIV RNA data are calculated on the log10 scale as log10(week X RNA copies/mL)\n\nFor this analysis, HIV-1 RNA values (copies per mL) that were censored below the lower limit of quantification (LLQ) were imputed to be equal to the LLQ - 1. The LLQ was considered to be 40 copies/mL. Viral load was calculated on the log10 scale as log10(week X RNA). Viral load suppression was also measured as copies < 40.\n\nThe log10 (week X RNA) values were averaged by site and those averages were analyzed.']"
0,133,['NCT03488264'],[],[],"['10 minutes', '5 minutes']",[],['Duke University'],"['Paula Tanabe, PhD']",['Principal Investigator'],['Completed'],['No'],['No'],[],[],[],[],[],[],"['October 27, 2018']",['Actual'],"['The Sickle Cell Disease Health-Related Stigma Scale (SCD-HRSS) will assess stigma. SCD-HRSS has 4 subscales that measure stigma from the public, doctors, nurses, and family; and consists of 40 items on a 6 point Likert scale. It is scored by obtaining the sum of the mean score of the four subscales (subscales: 10-60; total scale: 40-240). Higher scores indicate higher perceived stigma.', 'The Measure of Sickle Cell Stigma (MoSCS) will assess stigma. MoSCS consists of 11-items with 4 subscales assessing social exclusion, internalized stigma, disclosure concerns, and expected discrimination. It is measured on a 6 point Likert scale; scores range from 6-36 and are obtained by summing and averaging the total scale. Higher scores indicate higher perceived stigma.']"
0,134,['NCT01873482'],[],[],['During the first hour after the intervention'],[],['Duke University'],"['Kenneth Wilson, MD']",['Principal Investigator'],['Completed'],[],[],['Not Applicable'],[],[],[],[],[],['May 2014'],['Actual'],[]
0,135,['NCT02829073'],[],[],"['Baseline and two, four, and six months after enrollment']",[],['U.S. Army Aeromedical Research Laboratory'],"['William A Ahroon, Ph.D.']",['Principal Investigator'],['Unknown status'],['No'],[],['Not Applicable'],[],[],[],[],[],['December 2017'],['Anticipated'],['Change in TRQ score at 6 months compared to baseline']
0,136,['NCT01369030'],['1'],"['5.8', '5.0', '6.3']",['Baseline to Endpoint (90 days)'],"['14.6', '6.1', '8.5', '37.5', '7.0']","['Vanderbilt University School of Medicine', 'Mood Disorders Clinic at Moses Cone Family Practice Center']","['Richard C Shelton, M.D.', 'Sloan Manning, M.D.']","['Principal Investigator', 'Principal Investigator']",['Completed'],['No'],[],[],['lbarrentine@pamlab.com'],"['Pamlab, Inc.']",['985-867-5788'],[],"['Lori W Barrentine, MS, PA-C, Director of Clinical Affairs']",['April 2012'],['Actual'],"['The PHQ-9 is a depression scale used to assess brief depression severity by rating symptoms and functional impairment experienced in the last two weeks. The questionnaire contains a total of 9 questions, and each question is scored on a range from 0-3. The minimum value ""0"" represents not at all, ""1"" several days, ""2"" indicates more than half the days, and the maximum value ""3"" stands for nearly every day. The total possible range is 0-27. The total number of each 0, 1, 2, 3 is added and multiplied by its value (0=0, 1=1, etc.) to produce a total score generated from the subtotal sum. The PHQ-9 total score is interpreted as follows: 0-4 represents minimal depression, 5-9 as mild depression, 10-14 as moderate depression, 15-19 moderately severe depression, and 20-27 severe depression.']"
0,137,['NCT01568424'],"['4', '2', '6', '0', '0', '5', '6', '6', '59', '62', '55', '62', '54', '62', '60', '62', '1.6', '1.7', '1.6', '1.8', '7.7', '1.8', '1.8', '1.9', '7', '9', '9', '8', '9', '10', '12', '14', '7', '0.5', '0.6', '0.6', '0.5', '0.6', '0.6', '0.6', '0.4', '0.6', '0.5', '0.6', '0.3', '0.9', '0.7', '0.2', '0.7', '0.4', '0.2']",[],['30 days post device removal'],"['80', '11', '11', '10', '12', '11', '10', '12', '11', '72', '74', '74', '75', '79', '77', '73', '72', '2.4', '2.2', '2.9', '3.0', '7.7', '2.7', '2.2', '2.3', '27', '27', '26', '33', '28', '22', '28', '31', '24', '1.4', '1.3', '1.1', '1.2', '1.0', '1.0', '1.2', '1.3', '1.3', '1.1', '3.0', '3.0', '2.8', '1.8', '1.3', '2.0', '1.3', '0.8']",['Abbott Medical Devices'],"['Mark Macedo, BSN']",['Study Director'],['Completed'],['No'],[],['Not Applicable'],['psood@sjm.com'],['St. Jude Medical'],['+1.781.852.8334'],[],['Poornima Sood'],['February 2014'],['Actual'],['In patients who recover and do not go on to transplantation or a long-term device: Survival to 30 days post-support or to hospital discharge (whichever is longer).\n\nIn patients who do not recover and are bridged to transplant or a long-term system: Survival to induction of anesthesia for implantation of a long-term device or heart transplant.']
0,138,['NCT02406599'],[],[],"['Participants will be followed only for the initial lumpectomy duration. information will be available 2-3 weeks (avarage) from initial lumpectomy date', 'Participants will be followed only for the initial lumpectomy duration. information will be available 2-3 weeks (avarage) from initial lumpectomy date']",[],[],[],[],['Recruiting'],['No'],[],['Not Applicable'],[],[],[],[],[],"['March 31, 2020']",['Anticipated'],"['Sensitivity and Specificity at the margin level;', 'ISR - Positive Margin on the Main ex-vivo lumpectomy specimen after the initial lumpectomy surgery, that was not addressed by taking a shaving(s) corresponding to the positive margin(s).']"
0,139,['NCT03965195'],[],[],['Up to 8 months each influenza season'],[],"['Insight Therapeutics, LLC', 'Insight Therapeutics, LLC']","['H. Edward Davidson, PharmD, MPH', 'Stefan Gravenstein, MD, MPH']","['Principal Investigator', 'Principal Investigator']","['Active, not recruiting']",['No'],[],['Phase 4'],[],[],[],[],[],['August 2021'],['Anticipated'],['To determine the differences in all-cause hospitalization rates during the 2019-20 and 2020-21 influenza seasons experienced by all long-stay nursing home residents 18 years of age and older in facilities randomized to offer either quadrivalent recombinant influenza vaccine (RIV4) or standard dose quadrivalent influenza vaccine (IV4).']
0,140,['NCT01368549'],[],[],"['Baseline, Week 6 and Week 12']",[],['Endocrinology Associates'],"['Bruce Trippe, M.D.']",['Principal Investigator'],['Unknown status'],['No'],[],[],[],[],[],[],[],['January 2012'],['Anticipated'],[]
0,141,['NCT01370954'],[],[],"['Baseline, Week 6 and Week 12']",[],['Falls Neurology and Memory Center'],"['Donald E Schmechel, M.D.']",['Principal Investigator'],['Completed'],['No'],[],[],[],[],[],[],[],['November 2012'],['Actual'],"[""The QOL-AD is a brief, 13-item measure designed specifically to obtain a rating of the patient's Quality of Life.""]"
0,142,['NCT01339546'],[],[],['1) 2001-2009 inclusive (9 years) and 2) 2011-2013 inclusive (3 years)'],[],['Pfizer'],['Pfizer CT.gov Call Center'],['Study Director'],['Completed'],['No'],[],[],[],[],[],[],[],"['June 30, 2017']",['Actual'],[]
0,143,['NCT02252159'],[],[],"['Every 3 months for approximately 36 months', 'Every 3 months for approximately 36 months', 'Every 3 months for approximately 36 months', 'Every 3 months for approximately 36 months', 'Every 3 months for approximately 36 months']",[],['Incyte Corporation'],"['Philomena Colucci, DO, MS']",['Study Director'],"['Active, not recruiting']",['No'],['No'],[],[],[],[],[],[],['August 2019'],['Anticipated'],"['Healthcare resources were defined as a. Medical visits (including Office visits, ER visits, and hospitalizations), b. phlebotomy (PHL) procedures and c. prescriptions (including PV-related prescriptions, PV-related over-the-counter (OTC) medications, and prescription medications for co-morbid conditions).']"
0,144,['NCT04072289'],[],[],"['12 months', '12 months']",[],"['United States Naval Medical Center, San Diego', 'Wilford Hall Air Force Hospital', 'Ft. Belvoir Army Hospital']","['John B. Cason, M.D.', 'Matthew C. Caldwell, M.D.', 'Bruce A Rivers, M.D.']","['Principal Investigator', 'Principal Investigator', 'Principal Investigator']",['Recruiting'],['Yes'],[],['Not Applicable'],[],[],[],[],[],['September 2021'],['Anticipated'],"['manifest refraction spherical equivalent and manifest refractive cylinder refraction', 'uncorrected visual acuity of 20/40 or better']"
0,145,['NCT04423770'],[],[],['18 months'],[],['American Dental Association Science and Research Institute'],"['Cameron G Estrich, MPH, PhD']",['Principal Investigator'],"['Active, not recruiting']",['No'],['No'],[],[],[],[],[],[],"['June 8, 2021']",['Anticipated'],['COVID-19 case as confirmed by clinician and/or detection of SARS-CoV-2 RNA or a specific antigen in a clinical specimen']
0,146,['NCT01358552'],[],[],['Week 4'],[],"['Noe Lira, M.D.']","['Noe Lira, M.D.']",['Principal Investigator'],['Terminated'],['No'],[],[],[],[],[],[],[],['March 2012'],['Actual'],"['To collect data from patient surveys on the patient utilization and effectiveness of Néevo®/NéevoDHA® in a ""real world"" setting.']"
0,147,['NCT02856646'],[],[],"['Up to five years', 'Up to five years', 'Up to five years', 'Up to five years', 'Up to 5 years', 'Up to 5 years']",[],['Bristol-Myers Squibb'],['Bristol-Myers Squibb'],['Study Director'],['Recruiting'],['No'],['No'],[],[],[],[],[],[],"['September 28, 2023']",['Anticipated'],"['What are the treatment patterns of therapies used to treat cHL (ie, incorporation of novel chemotherapy or non-chemotherapy to upfront therapy, chemotherapy/radiation and/or transplant sparring patterns, incorporation of immune checkpoint agents or other investigational therapies)']"
0,148,['NCT01940679'],[],[],"['15 minute, 2 hrs, 4 hrs and 6 hrs after consumption of n-3 rich food item']",[],['U.S. Army Research Institute of Environmental Medicine'],"['Tracey J Smith, PhD']",['Principal Investigator'],['Completed'],['No'],[],['Not Applicable'],[],[],[],[],[],['December 2013'],['Actual'],[]
0,149,['NCT02951598'],[],[],['Baseline through Study Completion (36 Months)'],[],['Eli Lilly and Company'],"['Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)']",['Study Director'],"['Active, not recruiting']",['No'],[],['Not Applicable'],[],[],[],[],[],"['October 28, 2020']",['Anticipated'],[]
0,150,['NCT02988934'],[],[],['10 years'],[],[],[],[],['Recruiting'],[],['Yes'],[],[],[],[],[],[],['April 2026'],['Anticipated'],[]
0,151,['NCT01028300'],[],[],['24 months'],[],[],[],[],['Terminated'],['Yes'],[],['Not Applicable'],['mlotito@its.jnj.com'],['DePuy Synthes Spine'],['508-880-8045'],[],['Mark Lotito'],['March 2011'],['Actual'],[]
0,152,['NCT01034865'],[],[],[],[],['Stanford University'],['Mindie H. Nguyen'],['Principal Investigator'],['Completed'],[],[],[],[],[],[],[],[],['June 2009'],['Actual'],[]
0,153,['NCT02352532'],[],[],"['7 days', '5 minutes', '5 minutes', '7 days']",[],[],[],[],['Completed'],['No'],[],['Not Applicable'],[],[],[],[],[],['August 2016'],['Actual'],"['SWE images of the lumbar multifidus and paraspinal muscles will be acquired at rest and during sub-maximal isometric contraction. All SWE images will be obtained using a Supersonic Aixplorer ultrasound system with a 50mm 10-2 MHz linear array. The sub-maximal contraction of the lumbar multifidus will be elicited by a contralateral arm lift maneuver while holding a small hand weight following techniques outlined in our previous work.42 The weight used will depend on the participant\'s body weight and will elicit approximately 30% of the MVC of the lumbar multifidus muscle as previously shown by fine wire EMG.43 Participants weighing less than 68 kg (150 lbs) will use .68 kg (1.5 lbs), those between 68-90 kg (150-200 lbs) will use .91 kg (2 lbs), and those greater than 91 kg (200 lbs) will use 1.36 kg (3 lbs). Participants will be instructed as follows: ""lift your arm approximately 2 inches (5 cm) off the table"".', 'Pressure algometry will used in the current study to determine the most painful spinal level at baseline and as a secondary outcome measure, pain pressure threshold (PPT), to assess abnormalities in nociceptive processing or hyperalgisia 37,38. PPT measures have been found to be highly reliable,39-41 especially when taken by the same rater (ICC=0.94-.097) 40. A digital pressure algometer (Wagner Force Ten FDX, Wagner Instruments, Greenwich, CT) will be used to measure PPT in the lumbar multifidus and paraspinal muscles on the side that the participant reported as more symptomatic. The pressure algometer will held by the examiner directly perpendicular to the muscle belly, approximately 1.5 cm lateral to the spinous process. The algometer will be advanced at a rate of approximately 5N/sec. and participants are instructed to verbally signal when they first perceive the force exerted as painful. PPT at each location will taken three times and averaged to reduce variability.\n\nPressure', 'SWE images of the lumbar multifidus and paraspinal muscles will be acquired at rest and during sub-maximal isometric contraction. All SWE images will be obtained using a Supersonic Aixplorer ultrasound system with a 50mm 10-2 MHz linear array. The sub-maximal contraction of the lumbar multifidus will be elicited by a contralateral arm lift maneuver while holding a small hand weight following techniques outlined in our previous work.42 The weight used will depend on the participant\'s body weight and will elicit approximately 30% of the MVC of the lumbar multifidus muscle as previously shown by fine wire EMG.43 Participants weighing less than 68 kg (150 lbs) will use .68 kg (1.5 lbs), those between 68-90 kg (150-200 lbs) will use .91 kg (2 lbs), and those greater than 91 kg (200 lbs) will use 1.36 kg (3 lbs). Participants will be instructed as follows: ""lift your arm approximately 2 inches (5 cm) off the table"".', 'SWE images of the lumbar multifidus and paraspinal muscles will be acquired at rest and during sub-maximal isometric contraction. All SWE images will be obtained using a Supersonic Aixplorer ultrasound system with a 50mm 10-2 MHz linear array. The sub-maximal contraction of the lumbar multifidus will be elicited by a contralateral arm lift maneuver while holding a small hand weight following techniques outlined in our previous work.42 The weight used will depend on the participant\'s body weight and will elicit approximately 30% of the MVC of the lumbar multifidus muscle as previously shown by fine wire EMG.43 Participants weighing less than 68 kg (150 lbs) will use .68 kg (1.5 lbs), those between 68-90 kg (150-200 lbs) will use .91 kg (2 lbs), and those greater than 91 kg (200 lbs) will use 1.36 kg (3 lbs). Participants will be instructed as follows: ""lift your arm approximately 2 inches (5 cm) off the table"".']"
0,154,['NCT03198793'],[],[],['8 weeks'],[],"['Tulane University SOM, New Orleans, LA 70112']","['Keith C. Ferdinand, MD FACC']",['Study Chair'],['Completed'],['No'],[],['Phase 2'],[],[],[],[],[],"['October 16, 2018']",['Actual'],"['Office blood pressure will be taken at Day 0, Visit 3, Visit 4, Visit 4.1, and Visit 5 (Day 56).']"
0,155,['NCT01112917'],[],[],['6-months'],"['89', '0']",['Froedtert Hospital'],"['William S Rilling, MD']",['Principal Investigator'],['Completed'],['Yes'],[],['Not Applicable'],['andrea@brightresearchpartners.com'],['BRIGHT Research Partners'],['612-298-7460'],[],['Andrea Fenton Abbs - Study Director'],['September 2015'],['Actual'],"[""Technical success is defined as filter conversion without the loss of filter head components in the vasculature or incomplete opening of filtering legs. Further, in the analysis of the data, the sponsor did not count any filters as a 'technically' successful conversion when the operator was unable to snare the filter hook during an attempted conversion.""]"
0,156,['NCT01764269'],[],[],['11 days'],[],"['Columbia University', 'Columbia University']","['Melissa Stockwell, MD MPH', 'Philip LaRussa, MD']","['Principal Investigator', 'Principal Investigator']",['Completed'],['No'],[],['Not Applicable'],[],[],[],[],[],['April 2014'],['Actual'],['day of vaccination plus 10 more days']
0,157,['NCT03346603'],[],[],"['2 years', '2 years', '2 years']",[],[],[],[],"['Active, not recruiting']",['No'],['No'],[],[],[],[],[],[],"['February 28, 2019']",['Actual'],[]
0,158,['NCT04281290'],[],[],['7 days after operation'],[],"['University Medical Centre Ljubljana, Ljubljana, Slovenia', 'University Medical Centre Ljubljana, Ljubljana, Slovenia', 'Institute of Oncology, Ljubljana, Slovenia', 'University Medical Centre Ljubljana, Ljubljana, Slovenia', 'University Medical Centre Ljubljana, Ljubljana, Slovenia', 'University Medical Centre Ljubljana, Ljubljana, Slovenia', 'Institute of Oncology, Ljubljana, Slovenia', 'Institute of Oncology, Ljubljana, Slovenia', 'Institute of Oncology, Ljubljana, Slovenia']","['Mihajlo Djokic, MD, PhD', 'Blaz Trotovsek, MD, PhD', 'Gregor Sersa, PhD', 'Zan Cebron, MD', 'Miha Petric, MD', 'David Badovinac, MD', 'Masa Bosnjak, PhD', 'Bostjan Markelc, PhD', 'Maja Cemazar, PhD']","['Principal Investigator', 'Study Director', 'Study Director', 'Study Chair', 'Study Chair', 'Study Chair', 'Study Chair', 'Study Chair', 'Study Chair']",['Recruiting'],['Yes'],[],"['Phase 1', 'Phase 2']",[],[],[],[],[],"['February 1, 2021']",['Anticipated'],"['Every patient will be closely followed-up after operation with clinical examination and blood tests (hemogram, comprehensive metabolic panel, liver panel) according to the study protocol (day 1, 3, 7 after operation). In case of detected abnormalities additional imaging (US and/or CT) will take place. Findings will be noted and reported in line with Clavien-Dindo classification of surgical complications. The primary measure is to detect complications after surgery and to determine whether the complication is related to electrochemotherapy treatment or not.']"
0,159,['NCT04601103'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,160,['NCT04600856'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,161,['NCT04599907'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,162,['NCT04593875'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,163,['NCT04589507'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,164,['NCT04586205'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,165,['NCT04585646'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,166,['NCT04584788'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,167,['NCT04584099'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,168,['NCT04577898'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,169,['NCT04577456'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,170,['NCT04569253'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,171,['NCT04567186'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,172,['NCT04562532'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,173,['NCT04558970'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,174,['NCT04558632'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,175,['NCT04558047'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,176,['NCT04557917'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,177,['NCT04557891'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,178,['NCT04556968'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,179,['NCT04556474'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,180,['NCT04547920'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,181,['NCT04547712'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,182,['NCT04544670'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,183,['NCT04542525'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,184,['NCT04540913'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,185,['NCT04537013'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,186,['NCT04536168'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,187,['NCT04534764'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,188,['NCT04532099'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,189,['NCT04529616'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,190,['NCT04529109'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,191,['NCT04524247'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,192,['NCT04523545'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,193,['NCT04513574'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,194,['NCT04510857'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,195,['NCT04508335'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,196,['NCT04502758'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,197,['NCT04501146'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,198,['NCT04500821'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,199,['NCT04499521'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,200,['NCT04496752'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,201,['NCT04493021'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,202,['NCT04488666'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,203,['NCT04483791'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,204,['NCT04476784'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,205,['NCT04474054'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,206,['NCT04469218'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,207,['NCT04466930'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,208,['NCT04455997'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,209,['NCT04455854'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,210,['NCT04450108'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,211,['NCT04437615'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,212,['NCT04422990'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,213,['NCT04419714'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,214,['NCT04409158'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,215,['NCT04403542'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,216,['NCT04400643'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,217,['NCT04394546'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,218,['NCT04388787'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,219,['NCT04388722'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,220,['NCT04386785'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,221,['NCT04378764'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,222,['NCT04377438'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,223,['NCT04338971'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,224,['NCT04335981'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,225,['NCT04332640'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,226,['NCT04330001'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,227,['NCT04324593'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,228,['NCT04320823'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,229,['NCT04319887'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,230,['NCT04318132'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,231,['NCT04314947'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,232,['NCT04314700'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,233,['NCT04313725'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,234,['NCT04310566'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,235,['NCT04307446'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,236,['NCT04306744'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,237,['NCT04305119'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,238,['NCT04303273'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,239,['NCT04299386'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,240,['NCT04299009'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,241,['NCT04298359'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,242,['NCT04296773'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,243,['NCT04295499'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,244,['NCT04287036'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,245,['NCT04285541'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,246,['NCT04281940'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,247,['NCT04279522'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,248,['NCT04277455'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,249,['NCT04263532'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,250,['NCT04252183'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,251,['NCT04247581'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,252,['NCT04244357'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,253,['NCT04243369'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,254,['NCT04243239'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,255,['NCT04239885'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,256,['NCT04237207'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,257,['NCT04236869'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,258,['NCT04230486'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,259,['NCT04224155'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,260,['NCT04223609'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,261,['NCT04220060'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,262,['NCT04219891'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,263,['NCT04211441'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,264,['NCT04210622'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,265,['NCT04207749'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,266,['NCT04206839'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,267,['NCT04206384'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,268,['NCT04203745'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,269,['NCT04202419'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,270,['NCT04201340'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,271,['NCT04200898'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,272,['NCT04196907'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,273,['NCT04195581'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,274,['NCT04194307'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,275,['NCT04192630'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,276,['NCT04189913'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,277,['NCT04189081'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,278,['NCT04186806'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,279,['NCT04184973'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,280,['NCT04178720'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,281,['NCT04177771'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,282,['NCT04177212'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,283,['NCT04176965'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,284,['NCT04175340'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,285,['NCT04166032'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,286,['NCT04162652'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,287,['NCT04158466'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,288,['NCT04153292'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,289,['NCT04152642'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,290,['NCT04151992'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,291,['NCT04151290'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,292,['NCT04141007'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,293,['NCT04136158'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,294,['NCT04134286'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,295,['NCT04130490'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,296,['NCT04127188'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,297,['NCT04121754'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,298,['NCT04119609'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,299,['NCT04116879'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,300,['NCT04116866'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,301,['NCT04112784'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,302,['NCT04112628'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,303,['NCT04112134'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,304,['NCT04106934'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,305,['NCT04096495'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,306,['NCT04087395'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,307,['NCT04085328'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,308,['NCT04083742'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,309,['NCT04082078'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,310,['NCT04081727'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,311,['NCT04079842'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,312,['NCT04079816'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,313,['NCT04078490'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,314,['NCT04073823'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,315,['NCT04069585'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,316,['NCT04068818'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,317,['NCT04065659'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,318,['NCT04064606'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,319,['NCT04060524'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,320,['NCT04057105'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,321,['NCT04056494'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,322,['NCT04055519'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,323,['NCT04055324'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,324,['NCT04054401'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,325,['NCT04046627'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,326,['NCT04043234'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,327,['NCT04040933'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,328,['NCT04036747'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,329,['NCT04035161'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,330,['NCT04033315'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,331,['NCT04032977'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,332,['NCT04031989'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,333,['NCT04031976'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,334,['NCT04030702'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,335,['NCT04011826'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,336,['NCT04008836'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,337,['NCT04005586'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,338,['NCT04003831'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,339,['NCT03999944'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,340,['NCT03997357'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,341,['NCT03996187'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,342,['NCT03995355'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,343,['NCT03992768'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,344,['NCT03991468'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,345,['NCT03972995'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,346,['NCT03971721'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,347,['NCT03969875'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,348,['NCT03967184'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,349,['NCT03964831'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,350,['NCT03953274'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,351,['NCT03950895'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,352,['NCT03949335'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,353,['NCT03944629'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,354,['NCT03942016'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,355,['NCT03941912'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,356,['NCT03934463'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,357,['NCT03934125'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,358,['NCT03931213'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,359,['NCT03925545'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,360,['NCT03920280'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,361,['NCT03918928'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,362,['NCT03912584'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,363,['NCT03911700'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,364,['NCT03898778'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,365,['NCT03897751'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,366,['NCT03897712'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,367,['NCT03895034'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,368,['NCT03888352'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,369,['NCT03872609'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,370,['NCT03872466'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,371,['NCT03871179'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,372,['NCT03864848'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,373,['NCT03864081'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,374,['NCT03862300'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,375,['NCT03858140'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,376,['NCT03851510'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,377,['NCT03839199'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,378,['NCT03835026'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,379,['NCT03812679'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,380,['NCT03805074'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,381,['NCT03799549'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,382,['NCT03790046'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,383,['NCT03789669'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,384,['NCT03788551'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,385,['NCT03782116'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,386,['NCT03779984'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,387,['NCT03771521'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,388,['NCT03771352'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,389,['NCT03764254'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,390,['NCT03748823'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,391,['NCT03748771'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,392,['NCT03748316'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,393,['NCT03748264'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,394,['NCT03736798'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,395,['NCT03730480'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,396,['NCT03729024'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,397,['NCT03728309'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,398,['NCT03716492'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,399,['NCT03713281'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,400,['NCT03708393'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,401,['NCT03706430'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,402,['NCT03704636'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,403,['NCT03700372'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,404,['NCT03700047'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,405,['NCT03696316'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,406,['NCT03692741'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,407,['NCT03685136'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,408,['NCT03682432'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,409,['NCT03681886'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,410,['NCT03681496'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,411,['NCT03678103'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,412,['NCT03677388'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,413,['NCT03670277'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,414,['NCT03663010'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,415,['NCT03642431'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,416,['NCT03641937'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,417,['NCT03631550'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,418,['NCT03628898'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,419,['NCT03617822'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,420,['NCT03614130'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,421,['NCT03613363'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,422,['NCT03611101'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,423,['NCT03604900'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,424,['NCT03604562'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,425,['NCT03604432'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,426,['NCT03601182'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,427,['NCT03600194'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,428,['NCT03599271'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,429,['NCT03589911'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,430,['NCT03586167'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,431,['NCT03578302'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,432,['NCT03574259'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,433,['NCT03564366'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,434,['NCT03560141'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,435,['NCT03550807'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,436,['NCT03540576'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,437,['NCT03538561'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,438,['NCT03525704'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,439,['NCT03523208'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,440,['NCT03508778'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,441,['NCT03502200'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,442,['NCT03500341'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,443,['NCT03497910'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,444,['NCT03488849'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,445,['NCT03488238'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,446,['NCT03482297'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,447,['NCT03477370'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,448,['NCT03467204'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,449,['NCT03465514'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,450,['NCT03462576'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,451,['NCT03451786'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,452,['NCT03442842'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,453,['NCT03441971'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,454,['NCT03441880'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,455,['NCT03441477'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,456,['NCT03439189'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,457,['NCT03435224'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,458,['NCT03435211'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,459,['NCT03431883'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,460,['NCT03423251'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,461,['NCT03421145'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,462,['NCT03418545'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,463,['NCT03408444'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,464,['NCT03388138'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,465,['NCT03384381'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,466,['NCT03372434'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,467,['NCT03372343'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,468,['NCT03371160'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,469,['NCT03366194'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,470,['NCT03351192'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,471,['NCT03345121'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,472,['NCT03345017'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,473,['NCT03339388'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,474,['NCT03336944'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,475,['NCT03329794'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,476,['NCT03323515'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,477,['NCT03315117'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,478,['NCT03299933'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,479,['NCT03275532'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,480,['NCT03272308'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,481,['NCT03269097'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,482,['NCT03268356'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,483,['NCT03268265'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,484,['NCT03267134'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,485,['NCT03257410'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,486,['NCT03251079'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,487,['NCT03246503'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,488,['NCT03242148'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,489,['NCT03239574'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,490,['NCT03236519'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,491,['NCT03235791'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,492,['NCT03233945'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,493,['NCT03230877'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,494,['NCT03230747'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,495,['NCT03219567'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,496,['NCT03198988'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,497,['NCT03190564'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,498,['NCT03182660'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,499,['NCT03172949'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,500,['NCT03150407'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,501,['NCT03148613'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,502,['NCT03147820'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,503,['NCT03147482'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,504,['NCT03147417'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,505,['NCT03143127'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,506,['NCT03142594'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,507,['NCT03142581'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,508,['NCT03138369'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,509,['NCT03138343'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,510,['NCT03134989'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,511,['NCT03132363'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,512,['NCT03132350'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,513,['NCT03129152'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,514,['NCT03128840'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,515,['NCT03128632'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,516,['NCT03127566'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,517,['NCT03127540'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,518,['NCT03127527'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,519,['NCT03127501'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,520,['NCT03127488'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,521,['NCT03125135'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,522,['NCT03125122'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,523,['NCT03125109'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,524,['NCT03125096'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,525,['NCT03125044'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,526,['NCT03124992'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,527,['NCT03124953'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,528,['NCT03124940'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,529,['NCT03124888'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,530,['NCT03124849'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,531,['NCT03124810'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,532,['NCT03124745'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,533,['NCT03124732'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,534,['NCT03124719'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,535,['NCT03124706'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,536,['NCT03124264'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,537,['NCT03124251'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,538,['NCT03123380'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,539,['NCT03123341'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,540,['NCT03122379'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,541,['NCT03120702'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,542,['NCT03100760'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,543,['NCT03098602'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,544,['NCT03073148'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,545,['NCT03072186'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,546,['NCT03066063'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,547,['NCT03038074'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,548,['NCT03035318'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,549,['NCT03034902'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,550,['NCT03021707'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,551,['NCT03021473'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,552,['NCT03019107'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,553,['NCT03017742'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,554,['NCT03003767'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,555,['NCT02995421'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,556,['NCT02986789'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,557,['NCT02972892'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,558,['NCT02970799'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,559,['NCT02966210'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,560,['NCT02957071'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,561,['NCT02956928'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,562,['NCT02948751'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,563,['NCT02938637'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,564,['NCT02922621'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,565,['NCT02919566'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,566,['NCT02918942'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,567,['NCT02916823'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,568,['NCT02913560'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,569,['NCT02911376'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,570,['NCT02910674'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,571,['NCT02907203'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,572,['NCT02904382'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,573,['NCT02888626'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,574,['NCT02872844'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,575,['NCT02870959'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,576,['NCT02870881'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,577,['NCT02863796'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,578,['NCT02863432'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,579,['NCT02862080'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,580,['NCT02858089'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,581,['NCT02856490'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,582,['NCT02849847'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,583,['NCT02842970'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,584,['NCT02841397'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,585,['NCT02833571'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,586,['NCT02811328'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,587,['NCT02810080'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,588,['NCT02805933'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,589,['NCT02805777'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,590,['NCT02800057'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,591,['NCT02799342'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,592,['NCT02799329'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,593,['NCT02795689'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,594,['NCT02787343'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,595,['NCT02784431'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,596,['NCT02771119'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,597,['NCT02764580'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,598,['NCT02761759'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,599,['NCT02756260'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,600,['NCT02746289'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,601,['NCT02746120'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,602,['NCT02719444'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,603,['NCT02716155'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,604,['NCT02712931'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,605,['NCT02711254'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,606,['NCT02699021'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,607,['NCT02698787'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,608,['NCT02698397'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,609,['NCT02697604'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,610,['NCT02686450'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,611,['NCT02684110'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,612,['NCT02680964'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,613,['NCT02680860'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,614,['NCT02662049'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,615,['NCT02638883'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,616,['NCT02634996'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,617,['NCT02634554'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,618,['NCT02634125'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,619,['NCT02631213'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,620,['NCT02626624'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,621,['NCT02624739'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,622,['NCT02622919'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,623,['NCT02599519'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,624,['NCT02597296'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,625,['NCT02596464'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,626,['NCT02579486'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,627,['NCT02576210'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,628,['NCT02561052'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,629,['NCT02553395'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,630,['NCT02548429'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,631,['NCT02543814'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,632,['NCT02540577'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,633,['NCT02540564'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,634,['NCT02535234'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,635,['NCT02525783'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,636,['NCT02517645'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,637,['NCT02506400'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,638,['NCT02495116'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,639,['NCT02480829'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,640,['NCT02474784'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,641,['NCT02474771'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,642,['NCT02474758'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,643,['NCT02458378'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,644,['NCT02455063'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,645,['NCT02441634'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,646,['NCT02436005'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,647,['NCT02430441'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,648,['NCT02405871'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,649,['NCT02403167'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,650,['NCT02396914'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,651,['NCT02388425'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,652,['NCT02383082'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,653,['NCT02380716'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,654,['NCT02380014'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,655,['NCT02365545'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,656,['NCT02365467'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,657,['NCT02364375'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,658,['NCT02353377'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,659,['NCT02343068'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,660,['NCT02340832'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,661,['NCT02327598'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,662,['NCT02325609'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,663,['NCT02322840'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,664,['NCT02312141'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,665,['NCT02300974'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,666,['NCT02289534'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,667,['NCT02284321'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,668,['NCT02283125'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,669,['NCT02280577'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,670,['NCT02275624'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,671,['NCT02272114'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,672,['NCT02271087'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,673,['NCT02268227'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,674,['NCT02255539'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,675,['NCT02239263'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,676,['NCT02231034'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,677,['NCT02223663'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,678,['NCT02218450'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,679,['NCT02195362'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,680,['NCT02195128'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,681,['NCT02191800'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,682,['NCT02187458'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,683,['NCT02167880'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,684,['NCT02166073'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,685,['NCT02142465'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,686,['NCT02142374'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,687,['NCT02142023'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,688,['NCT02141334'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,689,['NCT02134236'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,690,['NCT02124538'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,691,['NCT02108275'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,692,['NCT02089646'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,693,['NCT02086812'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,694,['NCT02085174'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,695,['NCT02082847'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,696,['NCT02070601'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,697,['NCT02036385'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,698,['NCT02020447'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,699,['NCT02006251'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,700,['NCT02004249'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,701,['NCT02003105'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,702,['NCT01989390'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,703,['NCT01989377'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,704,['NCT01988727'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,705,['NCT01988025'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,706,['NCT01984151'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,707,['NCT01973621'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,708,['NCT01966211'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,709,['NCT01957982'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,710,['NCT01951131'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,711,['NCT01950767'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,712,['NCT01940458'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,713,['NCT01940211'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,714,['NCT01937000'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,715,['NCT01936987'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,716,['NCT01916083'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,717,['NCT01906736'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,718,['NCT01905241'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,719,['NCT01896141'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,720,['NCT01894698'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,721,['NCT01883557'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,722,['NCT01882309'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,723,['NCT01877369'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,724,['NCT01874925'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,725,['NCT01867008'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,726,['NCT01859975'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,727,['NCT01854879'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,728,['NCT01847846'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,729,['NCT01835769'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,730,['NCT01835366'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,731,['NCT01827488'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,732,['NCT01820741'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,733,['NCT01801995'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,734,['NCT01801241'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,735,['NCT01795807'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,736,['NCT01795118'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,737,['NCT01792869'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,738,['NCT01790867'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,739,['NCT01787981'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,740,['NCT01777880'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,741,['NCT01773941'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,742,['NCT01773265'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,743,['NCT01747265'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,744,['NCT01738230'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,745,['NCT01738165'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,746,['NCT01733264'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,747,['NCT01733251'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,748,['NCT01724541'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,749,['NCT01721122'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,750,['NCT01715454'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,751,['NCT01700764'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,752,['NCT01697813'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,753,['NCT01697774'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,754,['NCT01674400'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,755,['NCT01670006'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,756,['NCT01662479'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,757,['NCT01660113'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,758,['NCT01658189'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,759,['NCT01652846'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,760,['NCT01643200'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,761,['NCT01640795'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,762,['NCT01630707'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,763,['NCT01629836'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,764,['NCT01627405'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,765,['NCT01614925'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,766,['NCT01613742'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,767,['NCT01610505'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,768,['NCT01610349'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,769,['NCT01607606'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,770,['NCT01604967'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,771,['NCT01597271'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,772,['NCT01591369'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,773,['NCT01582386'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,774,['NCT01575210'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,775,['NCT01564589'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,776,['NCT01560156'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,777,['NCT01558609'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,778,['NCT01556750'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,779,['NCT01546831'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,780,['NCT01546584'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,781,['NCT01533831'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,782,['NCT01533103'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,783,['NCT01532752'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,784,['NCT01532440'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,785,['NCT01524263'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,786,['NCT01515618'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,787,['NCT01513512'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,788,['NCT01499030'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,789,['NCT01494376'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,790,['NCT01480570'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,791,['NCT01476826'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,792,['NCT01473134'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,793,['NCT01470079'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,794,['NCT01464580'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,795,['NCT01463618'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,796,['NCT01462955'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,797,['NCT01450540'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,798,['NCT01443299'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,799,['NCT01443286'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,800,['NCT01442389'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,801,['NCT01436669'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,802,['NCT01436461'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,803,['NCT01414491'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,804,['NCT01414270'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,805,['NCT01412112'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,806,['NCT01408017'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,807,['NCT01403584'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,808,['NCT01392261'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,809,['NCT01379794'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,810,['NCT01374243'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,811,['NCT01370785'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,812,['NCT01367171'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,813,['NCT01365689'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,814,['NCT01358682'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,815,['NCT01336868'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,816,['NCT01313351'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,817,['NCT01313195'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,818,['NCT01311726'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,819,['NCT01307709'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,820,['NCT01297751'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,821,['NCT01286792'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,822,['NCT01258400'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,823,['NCT01246115'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,824,['NCT01240733'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,825,['NCT01239576'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,826,['NCT01234480'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,827,['NCT01230398'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,828,['NCT01201889'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,829,['NCT01194752'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,830,['NCT01194739'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,831,['NCT01194726'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,832,['NCT01183195'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,833,['NCT01180257'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,834,['NCT01171066'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,835,['NCT01166607'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,836,['NCT01164527'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,837,['NCT01158963'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,838,['NCT01150227'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,839,['NCT01148251'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,840,['NCT01147094'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,841,['NCT01145651'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,842,['NCT01145378'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,843,['NCT01143116'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,844,['NCT01140919'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,845,['NCT01127347'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,846,['NCT01112475'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,847,['NCT01108822'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,848,['NCT01106222'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,849,['NCT01103869'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,850,['NCT01100983'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,851,['NCT01098682'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,852,['NCT01097824'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,853,['NCT01092871'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,854,['NCT01077141'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,855,['NCT01070992'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,856,['NCT01067040'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,857,['NCT01062464'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,858,['NCT01062412'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,859,['NCT01062217'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,860,['NCT01057134'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,861,['NCT01043497'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,862,['NCT01039064'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,863,['NCT01037439'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,864,['NCT01030588'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,865,['NCT01029028'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,866,['NCT01022554'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,867,['NCT01016236'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,868,['NCT01008202'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,869,['NCT01000454'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,870,['NCT00993772'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,871,['NCT00990483'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,872,['NCT00990210'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,873,['NCT00986908'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,874,['NCT00981188'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,875,['NCT00979498'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,876,['NCT00979030'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,877,['NCT00969748'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,878,['NCT00968474'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,879,['NCT00961519'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,880,['NCT00960947'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,881,['NCT00957632'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,882,['NCT00957138'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,883,['NCT00956618'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,884,['NCT00955331'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,885,['NCT00946075'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,886,['NCT00944411'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,887,['NCT00942942'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,888,['NCT00935974'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,889,['NCT00932789'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,890,['NCT00924716'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,891,['NCT00911040'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,892,['NCT00906958'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,893,['NCT00906815'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,894,['NCT00906009'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,895,['NCT00905749'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,896,['NCT00903058'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,897,['NCT00901667'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,898,['NCT00900705'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,899,['NCT00889746'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,900,['NCT00878982'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,901,['NCT00877916'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,902,['NCT00865930'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,903,['NCT00865735'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,904,['NCT00863486'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,905,['NCT00863447'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,906,['NCT00858091'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,907,['NCT00850434'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,908,['NCT00850109'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,909,['NCT00846820'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,910,['NCT00843752'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,911,['NCT00840619'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,912,['NCT00824018'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,913,['NCT00821769'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,914,['NCT00820040'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,915,['NCT00819130'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,916,['NCT00818922'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,917,['NCT00810498'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,918,['NCT00810459'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,919,['NCT00809406'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,920,['NCT00806052'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,921,['NCT00802750'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,922,['NCT00800891'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,923,['NCT00799981'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,924,['NCT00794534'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,925,['NCT00791414'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,926,['NCT00790621'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,927,['NCT00789334'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,928,['NCT00788450'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,929,['NCT00788437'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,930,['NCT00782119'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,931,['NCT00781651'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,932,['NCT00781222'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,933,['NCT00780065'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,934,['NCT00779623'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,935,['NCT00777283'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,936,['NCT00776893'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,937,['NCT00776815'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,938,['NCT00776152'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,939,['NCT00773903'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,940,['NCT00773721'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,941,['NCT00769340'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,942,['NCT00767910'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,943,['NCT00766727'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,944,['NCT00764491'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,945,['NCT00764452'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,946,['NCT00760643'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,947,['NCT00759694'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,948,['NCT00758979'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,949,['NCT00758875'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,950,['NCT00758095'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,951,['NCT00756496'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,952,['NCT00754598'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,953,['NCT00748917'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,954,['NCT00748033'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,955,['NCT00747266'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,956,['NCT00739245'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,957,['NCT00732264'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,958,['NCT00732134'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,959,['NCT00728702'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,960,['NCT00727805'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,961,['NCT00727688'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,962,['NCT00726297'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,963,['NCT00726024'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,964,['NCT00725816'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,965,['NCT00725699'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,966,['NCT00716313'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,967,['NCT00690742'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,968,['NCT00681057'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,969,['NCT00680251'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,970,['NCT00678808'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,971,['NCT00676546'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,972,['NCT00676078'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,973,['NCT00670137'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,974,['NCT00660556'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,975,['NCT00659139'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,976,['NCT00653211'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,977,['NCT00639340'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,978,['NCT00630526'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,979,['NCT00617630'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,980,['NCT00617162'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,981,['NCT00616226'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,982,['NCT00615342'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,983,['NCT00608647'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,984,['NCT00597571'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,985,['NCT00591513'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,986,['NCT00589069'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,987,['NCT00588601'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,988,['NCT00587613'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,989,['NCT00587509'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,990,['NCT00586456'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,991,['NCT00579176'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,992,['NCT00578513'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,993,['NCT00578487'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,994,['NCT00576953'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,995,['NCT00561847'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,996,['NCT00542477'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,997,['NCT00529685'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,998,['NCT00506220'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,999,['NCT00448812'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
0,1000,['NCT00350259'],[],[],[],[],[],[],[],['Withheld'],[],[],[],[],[],[],[],[],[],[],[]
